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A B S T R A C T
Background
Recombinant factor VIIa (rFVIIa) is licensed for use in patients with haemophilia and inhibitory allo-antibodies and for prophylaxis
and treatment of patients with congenital factor VII deficiency. It is also used for off-license indications to prevent bleeding in operations
where blood loss is likely to be high, and/or to stop bleeding that is proving difficult to control by other means. This is the third version
of the 2007 Cochrane review on the use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without
haemophilia, and has been updated to incorporate recent trial data.
Objectives
To assess the effectiveness of rFVIIa when used therapeutically to control active bleeding or prophylactically to prevent (excessive)
bleeding in patients without haemophilia.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and other medical databases up
to 23 March 2011.
Selection criteria
Randomised controlled trials (RCTs) comparing rFVIIa with placebo, or one dose of rFVIIa with another, in any patient population
(except haemophilia). Outcomes were mortality, blood loss or control of bleeding, red cell transfusion requirements, number of patients
transfused and thromboembolic adverse events.
Data collection and analysis
Two authors independently assessed potentially relevant studies for inclusion, extracted data and examined risk of bias. We considered
prophylactic and therapeutic rFVIIa studies separately.
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Main results
Twenty-nine RCTs were included: 28 were placebo-controlled, double-blind RCTs and one compared different doses of rFVIIa. In the
’Risk of bias’ assessment, most studies were found to have some threats to validity although therapeutic RCTs were found to be less
prone to bias than prophylactic RCTs.
Sixteen trials involving 1361 participants examined the prophylactic use of rFVIIa; 729 received rFVIIa. There was no evidence of
mortality benefit (risk ratio (RR) 1.04; 95% confidence interval (CI) 0.55 to 1.97). There was decreased blood loss (mean difference
(MD) -297 mL; 95% CI -416 to -178) and decreased red cell transfusion requirements (MD -261 mL; 95% CI -367 to -154) with
rFVIIa treatment; however, these values were likely overestimated due to the inability to incorporate data from trials (four RCTs in
the outcome of blood loss and three RCTs in the outcome of transfusion requirements) showing no difference of rFVIIa treatment
compared to placebo. There was a trend in favour of rFVIIa in the number of participants transfused (RR 0.85; 95% CI 0.72 to 1.01).
However, there was a trend against rFVIIa with respect to thromboembolic adverse events (RR 1.35; 95% CI 0.82 to 2.25).
Thirteen trials involving 2929 participants examined the therapeutic use of rFVIIa; 1878 received rFVIIa. There were no outcomes
where any observed advantage or disadvantage of rFVIIa over placebo could not have been observed by chance alone. There was a trend
in favour of rFVIIa for reducing mortality (RR 0.91; 95% CI 0.78 to 1.06). However, there was a trend against rFVIIa for increased
thromboembolic adverse events (RR 1.14; 95% CI 0.89 to 1.47).
When all trials were pooled together to examine the risk of thromboembolic events, a significant increase in total arterial events was
observed (RR 1.45; 95% CI 1.02 to 2.05).
Authors’ conclusions
The effectiveness of rFVIIa as a more general haemostatic drug, either prophylactically or therapeutically, remains unproven. The results
indicate increased risk of arterial events in patients receiving rFVIIa. The use of rFVIIa outside its current licensed indications should
be restricted to clinical trials.
P L A I N L A N G U A G E S U M M A R Y
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
The purpose of this review was to evaluate the evidence of effectiveness and safety for the use of recombinant factor VIIa (rFVIIa).
This drug has been used in patients who are either at risk of major bleeding (e.g. because of planned high-risk surgery), or who have
uncontrolled bleeding (e.g. related to trauma). There have been many articles in the literature describing the off-license use of this drug,
which often suggest benefit. However, most of the publications are based on small numbers of patients (in case reports or case series)
and may be affected by bias. Randomised controlled trials provide higher-quality research findings and allow us to assess the evidence
of drug effectiveness with more certainty.
This review included 29 randomised controlled trials with 4290 patients. The trials showed modest reductions in total blood loss or
red cells transfused (equivalent to less than one unit of red cell transfusion) with the use of rFVIIa. However, the reductions were likely
to be overestimated due to the limitations of the data. We also observed an increase in the risk of having a blood clot in the arteries
(such as a heart attack or stroke) in those patients receiving rFVIIa. When taken together, the data supporting the off-license use of
recombinant FVIIa are weak. The use of rFVIIa outside its current licensed indications should be restricted to clinical trials.
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B A C K G R O U N D
Recombinant activated factor VII (rFVIIa) (NovoSeven®, Novo
Nordisk, Denmark) has been manufactured and used clinically
for a number of years for the treatment of bleeding in individuals
with haemophilia and inhibitory antibodies to factor VIII (Lusher
1998) as well as other congenital bleeding disorders such as in-
herited factor VII deficiency and Glanzmann’s thrombasthenia.
More recently, the potential of rFVIIa to minimise or control se-
vere bleeding in a variety of medical and surgical situations has
engendered considerable interest (Hedner 2002). The hypothesis
that high-dose rFVIIa would be capable of enhancing haemostasis
at the local site of injury, without systemic activation of the coag-
ulation cascade and the risk of widespread inappropriate throm-
bosis, would clearly be an asset for clinical use (Key 2003a).
The initial evidence on the clinical role of rFVIIa for patients with-
out inherited defects of haemostasis was dominated by case reports
and small case series (Ahonen 2005; Greisen 2003; Key 2003b).
However, over the years, data from randomised controlled trials
have been reported, which should provide the most robust means
of evaluating drug effectiveness and safety. These trials have as-
sessed drug use in a variety of clinical scenarios in which rFVIIa
may have a role, including excessive surgical bleeding, uncon-
trolled medical bleeding and trauma. However, bleeding in these
clinical settings has multiple causes, including diffuse small ves-
sel oozing, dilution of clotting factors and platelets from mas-
sive transfusion, disseminated intravascular coagulation, hyperfib-
rinolysis, hypothermia (with slowing of the enzymatic reactions
in coagulation) and acidosis, and it is unclear what effect rFVIIa
would have on haemostasis in the setting of each or a combination
of these factors. Many hospitals report that off-label use of rFVIIa
as a general or ’universal haemostatic agent’ has been increasing
at least up until 2008 (Isbister 2008; Logan 2010; Logan 2011;
Roberts 2004).
One of the concerns about extending the use of a coagulation factor
treatment such as rFVIIa to different patient groups is the potential
for adverse effects, in particular the risk of thromboembolism (Levi
2010; O’Connell 2006).
To examine the effectiveness and safety of recombinant factor VIIa
with the addition of larger randomised controlled trials, we have
produced this third version of the Cochrane review on the use
of recombinant factor VIIa for the prevention and treatment of
bleeding in patients without haemophilia, which was first pub-
lished in 2007.
O B J E C T I V E S
The objective of this systematic review was to assess the effects of
recombinant factor VIIa (rFVIIa) when used for the prophylactic
or therapeutic management of haemorrhage in patients without
haemophilia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Patients at risk of blood loss due to surgery, or who had received
treatment to manage bleeding. We considered all age groups, but
we excluded patients with haemophilia or other haemostatic de-
fects (for example, Glanzmann’s thrombasthenia, inherited factor
VII deficiency).
Types of interventions
• RCTs comparing rFVIIa to prevent bleeding (for example,
before or during surgery) with no rFVIIa.
• RCTs comparing rFVIIa to treat bleeding (for example, in
the context of medical or surgical bleeding, or trauma) with no
rFVIIa.
• RCTs comparing rFVIIa with alternative treatments for the
prevention and/or treatment of haemorrhage.
• RCTs comparing different dose schedules of rFVIIa.
We documented details of co-interventions aimed at managing
bleeding, including the use of additional ’haemostatic’ drugs and
policies for transfusion.
Types of outcome measures
• Survival at fixed, relevant time periods, with mortality
evaluated by cause when possible (that is, as either haemorrhagic,
an adverse effect of the intervention, or not related to
intervention).
• Bleeding (within a predefined follow-up period post-
intervention), measured as response of bleeding (for example,
prevented, stopped, decreased, increased, no change), number
and/or duration of bleeding episodes, or severity of blood loss
(for example, by volume, rate or bleeding score).
• Number of red cell transfusions required (whether as units
transfused or episodes, in a follow-up period relevant to the
bleeding episode).
• Number of patients avoiding transfusions (for prophylactic
studies).
• Adverse effects of interventions (for example, thrombosis).
We identified other outcome information (for example, use of
blood products other than red cells, impact on operation times
and adverse events other than thromboembolic events) in study
reports during the preparation of the first version of this review.
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In the future, we will explore the value of these data in a separate
analysis.
Search methods for identification of studies
The searches were not restricted by language or publication status.
Searches were conducted by the authors, working independently
from the Cochrane Injuries Group Editorial Base.
Electronic searches
We searched the following databases on 23 March 2011.
• CENTRAL (Cochrane Central Register of Controlled
Trials, The Cochrane Library 2011, Issue 1)
• MEDLINE (1948 to 23 March 2011)
• EMBASE (1980 to 23 March 2011)
• CINAHL (1982 to 23 March 2011)
• UK Blood Transfusion & Tissue Transplantation Services
(UKBTS) Systematic Review Initiative (SRI) Transfusion
Evidence Library (www.transfusionevidencelibrary.com) (1980
to 23 March 2011)
• LILACS (1982 to 23 March 2011)
• KoreaMed (1997 to 23 March 2011)
• IndMed (1985 to 23 March 2011)
• PakMediNet (2001 to 23 March 2011)
• ISRCTN Register (23 March 2011)
• ClinicalTrials.gov (23 March 2011)
• EUDRACT (EU Clinical Trials Register) (23 March 2011)
• WHO ICTRP (International Clinical Trials Register
Portal) (23 March 2011)
In MEDLINE, we combined the search strategy with the
Cochrane optimal RCT search filter described in Chapter 6.4.11
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). In EMBASE and CINAHL, we combined search
strategies with adaptations of this RCT filter. Search strategies can
be found in Appendix 1, Appendix 2, Appendix 3, Appendix 4
and Appendix 5.
Searching other resources
In addition, we checked the reference lists of the RCTs identified
and of relevant reviews, including recently published systematic re-
views (Hsia 2008; You 2006). We contacted the authors of known
trials for information on any further trials of which they may be
aware, whether published, unpublished or ongoing, or to provide
additional data as required. We also carefully followed up ongoing
trials identified in the first version of this review and identified
new ongoing trials.
Data collection and analysis
Selection of studies
Two of the authors (ES, YL, SS or JB) screened all titles and ab-
stracts of papers identified by the database searches for relevance.
We excluded only clearly irrelevant studies at this stage; we assessed
all other studies on the basis of their full text for inclusion/exclu-
sion using the criteria indicated above. At this stage, two authors
independently assessed eligibility and noted any discrepancies in
their assessments. We only included trials available as full publi-
cations up to March 2011 (Figure 1).
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Figure 1. Figure 1. Flow diagram for selection of all randomized controlled trials for this review.
Data extraction and management
Aside from details relating to study quality, we extracted the fol-
lowing data.
• Study characteristics - place of publication, date of
publication, population characteristics, setting, intervention,
comparator and outcomes. A key purpose of these data was to
examine clinical heterogeneity in the included studies
independently from the analysis of results. Potential sources of
clinical heterogeneity in this specific review included details of
intervention (dose, frequency) and participant group (condition,
clinical setting).
• Results of included studies - we extracted data for each of
the main outcomes indicated in the review question. If an
included study did not contribute data on a particular outcome
we recorded the reason. We considered the possibility of the
selective reporting of results on particular outcomes. For
dichotomous outcomes, we recorded the numbers of outcomes
in treatment and control groups. For continuous outcomes, we
recorded means and standard deviations (SD). If median and
interquartile range (IQR) were available, we used the median as
the mean and converted the IQR to SD.
Two authors extracted data using data extraction forms that were
purposely created and piloted for this review. The authors re-
solved disagreements by consensus, recording the agreed data onto
a third summary data extraction form. One author transcribed
this into the systematic review computer software Review Man-
ager 5 (RevMan 2008); another author verified all data entry for
discrepancies.
Assessment of risk of bias in included studies
All authors used the following criteria for judging risk of bias from
the Cochrane Handbook for Systematic Reviews of Interventions ver-
sion 5.0.1 (Higgins 2011) to evaluate the methodological quality
of the included studies:
• generation of a random sequence;
• concealment of treatment allocation schedule;
• blinding of participants, personnel and outcome assessors;
• incomplete outcome data reporting;
• selective outcome reporting; and
• other potential threats to validity.
We rated these criteria using the ’Risk of bias’ assessment tool pro-
vided in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011). This assigns a rating of ’Yes’ (adequate),
’Unclear’ and ’No’ (clearly inadequate) to each specified method-
ological criterion. In addition, we added a criterion to the table to
indicate whether a power calculation was performed for the RCT.
A rating of ’Yes’ was assigned if both a power calculation was per-
formed and the target sample size was stated (regardless of whether
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or not this target was achieved), ’Unclear’ if a power calculation
was performed but a target sample size was not specified, and ’No’
if no power calculation was performed.
We used evaluation of themethodological quality of each included
study within the review in the following ways:
• either as a possible explanation for differences in results
between studies or to investigate heterogeneity; or
• in sensitivity analyses, examining the effect on overall
estimates of excluding studies of poor methodological quality.
Measures of treatment effect
We analysed data qualitatively and quantitatively. The preferred
form of summary result was a risk ratio (RR) for binary data and
mean difference (MD) for continuous data, both with 95% confi-
dence intervals (CI). When a study reported values on continuous
outcomes for subgroups of different doses of rFVIIa, we used the
mean of the reported values as an overall summary effect of rFVIIa
for the meta-analysis.
Assessment of heterogeneity
We examined statistical heterogeneity using the Chi2 test, the I2
statistic and visual inspection of graphs. We considered values of
I2 greater than 25% to indicate a level of heterogeneity at which
pooled estimates should be interpreted very cautiously and efforts
focused on understanding the cause of between-study variation in
results.Where the I2 was below 25%we explored the robustness of
any summary measures, particularly with respect to study quality.
Assessment of reporting biases
We examined publication bias using funnel plots produced using
RevMan 5 software for each of the outcome measures.
Data synthesis
We employed meta-analysis, using a fixed-effect model in the first
instance, but also evaluated the results from the random-effects
model. The results from the random-effects models are given in
recognition of the marked clinical heterogeneity between the in-
cluded studies.
Subgroup analysis and investigation of heterogeneity
One subgroup was pre-specified: rFVIIa dose. The cut-off used to
distinguish low fromhigh dose was less than 80µg/kg and equal to
or more than 80 µg/kg of rFVIIa, based on clinical opinion (and
was not strictly pre-specified). No differences between the low-
dose and high-dose outcomes were seen in the previous versions
nor in this version, therefore these analyses are not presented.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
See ’Characteristics of included studies’ and ’Characteristics of
ongoing studies’.
Results of the search
The updated search (conducted 23 March 2011) identified a total
of 140 new records since the last version, which three authors
(ES, YL, SS) reviewed independently. Figure 1 shows the study
selection sequentially for each of the updates of this review.
Twenty-seven RCTs as full publications up to 23March 2011 were
eligible for inclusion. For the purposes of this review,we considered
each of the studies by Boffard et al and Hauser et al as two separate
trials, because they both concerned two different types of trauma:
blunt (Boffard 2005a; Hauser 2010a) and penetrating (Boffard
2005b; Hauser 2010b). With these sub-populations, there was
a total of 29 RCTs for analysis (see ’Characteristics of included
studies’).
We identified a number of potentially eligible ongoing and com-
pleted (unpublished) trials from other registers, including the
meta-register of controlled trials (mRCT - includes ClinicalTri-
als.gov), the National Research Register, ClinicalStudyResults.org
and the Novo Nordisk list of rFVIIa trials. These trials are sum-
marised in the ’Characteristics of ongoing studies’ table. An addi-
tional table (Table 1) has been included in this update summaris-
ing the status of the ongoing studies from the last version of this
review (Lin 2011). Of the 11 studies in Table 1, five were com-
pleted and two were published.
Included studies
See ’Characteristics of included studies’.
Prophylactic trials
Sixteen RCTs assessed rFVIIa given prophylactically to prevent
bleeding (Table 2). Nine trials were single-centre and seven were
multi-centre. Eight were small with fewer than 50 patients ran-
domised (Diprose 2005; Essam 2007; Friederich 2003; Hanna
2010; Johansson 2007; Ma 2006; Pugliese 2007; Raobaikady
2005).
Participants
The clinical setting of the included studies varied (Table 2). Five
studies evaluated patients undergoing cardio-pulmonary bypass
(Diprose 2005; Ekert 2006; Essam 2007; Ma 2006; Gill 2009).
Six studies evaluated patients undergoing hepatic procedures: one
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in liver biopsy (Jeffers 2002), two in partial hepatectomy (Lodge
2005a; Shao 2006) and three in liver transplantation (Lodge
2005b; Planinsic 2005; Pugliese 2007). Five studies evaluated the
role of rFVIIa in a variety of other conditions: paediatric cran-
iofacial reconstruction (Hanna 2010), retropubic prostatectomy
(Friederich 2003), burn patients requiring excision and grafting
(Johansson 2007), pelvic fracture (Raobaikady 2005) and spinal
fusion surgery (Sachs 2007). Both Sachs 2007 and Gill 2009 were
considered with the prophylactic group as rFVIIa was adminis-
tered at the time of a defined bleeding trigger in the perioperative
setting.
All studies reported predefined exclusion criteria except Pugliese
2007. The main exclusions were evidence of pre-existing ’coag-
ulopathy’ in patients with known thromboembolic or vascular
disease. In addition, Diprose 2005 and Ma 2006 excluded pa-
tients who would refuse blood products while Hanna 2010 also
excluded patients with neurological disorders, and both Planinsic
2005 and Lodge 2005b excluded patients who had undergone
previous transplantation.
Intervention
Fifteen of 16 trials compared rFVIIa with placebo. rFVIIa was
given at a single dose in eight studies and as repeated dosing in
eight studies, with three studies administering repeated dosing
only if there was ongoing surgery or bleeding (Table 2). Thus there
were marked differences in the doses and schedules employed.
The differences are more apparent if the total dose administered
is considered. This varied from 5 µg/kg (Jeffers 2002) to 360 µg/
kg (Lodge 2005b; Sachs 2007).
Co-interventions
The two main groups of important co-interventions were the use
of additional ’haemostatic’ drugs and transfusion (Table 2). Red
cell transfusion protocols were provided in 13 studies with seven
studies outlining further guidelines for platelets and/or plasma.
Three studies provided no details on transfusion protocols (Ekert
2006; Jeffers 2002; Ma 2006). Co-interventions are also out-
lined in Table 2. Of particular interest for thromboembolic ad-
verse events, four studies described the use of lowmolecular weight
heparin (LMWH) in the perioperative (Raobaikady 2005) and
postoperative settings (Friederich 2003; Johansson 2007; Lodge
2005a).
Outcomes
The prophylactic studies reported a variety of primary outcome
measures (Table 2). However, the main outcome focus of the
included studies was either blood loss (primary outcome in
Friederich 2003; Raobaikady 2005; Sachs 2007), amount of blood
transfused (primary outcome in Ekert 2006; Friederich 2003;
Johansson 2007; Lodge 2005b; Planinsic 2005; Shao 2006), or
number of patients receiving allogeneic transfusion (primary out-
come inDiprose 2005; Lodge 2005a; Shao 2006). Four studies did
not define a primary outcome but collected data on blood loss and
transfusion requirements (Essam 2007; Hanna 2010; Ma 2006;
Pugliese 2007). Finally, one study in liver biopsy (Jeffers 2002)
used time to haemostasis and duration of normal prothrombin
time (PT) as its primary outcomes and one study used a primary
outcome of critical serious adverse events (Gill 2009).
All trials except Essam 2007 and Hanna 2010 reported ad-
verse events including deaths and thromboembolic events. Active
surveillance (planned ECG, troponin measurements or doppler
ultrasound) was performed in five prophylactic studies (Friederich
2003; Lodge 2005a; Lodge 2005b; Planinsic 2005; Shao 2006).
Other adverse events were reported, but the focus of this report is
on death and thromboembolic events, the latter being of particu-
lar concern when using a pro-coagulant agent.
Therapeutic trials
Thirteen RCTs assessed rFVIIa given therapeutically to treat es-
tablished bleeding (Table 3). All of the trials were multi-centre.
Three studies were small with fewer than 50 patients randomised
(Chuansumrit 2005; Mayer 2005b; Mayer 2006).
Participants
The clinical setting of the included studies varied (Table 3): four
studies in severe trauma (Boffard 2005a; Boffard 2005b; Hauser
2010a; Hauser 2010b), two studies in cirrhosis with acute upper
gastrointestinal bleeding (UGIB) (Bosch 2004; Bosch 2008), one
study in dengue haemorrhagic fever (Chuansumrit 2005), one
study in bleeding post-haematopoietic stem cell transplantation
(HSCT) (Pihusch 2005), four studies in spontaneous intracranial
haemorrhage (ICH) (Mayer 2005a; Mayer 2005b; Mayer 2006;
Mayer 2008) and one study in traumatic ICH (Narayan 2008).
All studies reported pre-defined exclusion criteria. Common ex-
clusions related to the severity of the condition being treated (all
trials) and evidence of an underlying clotting or bleeding diathe-
sis (Bosch 2004; Bosch 2008; Mayer 2005a; Mayer 2006; Mayer
2008; Narayan 2008). In all ICH trials, patients were excluded if
surgical intervention was planned within 24 hours.
Intervention
All clinical trials were placebo-controlled but the doses of rFVIIa
varied widely, as did its administration (Table 3). rFVIIa was given
as a single dose in the five ICH trials and as repeated dosing in the
other trials, with one study administering repeated dosing only if
there was ongoing bleeding (Chuansumrit 2005). The variation in
doses was most evident when estimating the total dose of rFVIIa
received. The minimum was 5 to 10 µg/kg in Mayer 2006 and
Mayer 2005b, extending to 1120 µg/kg in Pihusch 2005, a 100-
fold variation.
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Co-interventions
The two main groups of important co-interventions were the use
of additional ’haemostatic’ drugs and transfusion (Table 3). Five
studies described transfusion protocols (Bosch 2004; Bosch 2008;
Hauser 2010a; Hauser 2010b; Pihusch 2005). The five ICH stud-
ies did not provide a transfusion protocol, which was appropriate
as these patients are rarely transfused. The remaining three studies
(Boffard 2005a; Boffard 2005b; Chuansumrit 2005) did not pro-
vide transfusion protocols. Although these studies did not include
transfusion protocols, transfusion requirements were cited as the
primary outcome in Boffard 2005a and Boffard 2005b.
Outcomes
The therapeutic studies reported multiple outcome measures (see
Table 3 and ’Characteristics of included studies’). In themajority of
the included trials (Bosch 2004; Bosch 2008; Chuansumrit 2005;
Mayer 2005a; Pihusch 2005) the primary endpoint was a measure
of change in bleeding. By contrast, Boffard 2005a and Boffard
2005b defined the primary endpoint as transfusion requirements.
The primary endpoint in Mayer 2008 was a clinical outcome as
defined by the modified Rankin scale at day 90. Mayer 2005b,
Mayer 2006 and Narayan 2008 defined their primary outcome as
the frequency of adverse events that were (possibly or probably)
treatment-related. Hauser 2010a and Hauser 2010b measured all-
cause 30-day mortality as the primary outcome.
Again, other secondary outcomes for all included treatment tri-
als included adverse events, particularly deaths and thromboem-
bolic events, which were monitored either clinically or addition-
ally by Doppler ultrasound. Other adverse events were reported,
but deaths and thromboembolic events are the focus of this review.
Sources of support
Nine of 16 prophylactic trials were either supported by Novo
Nordisk, the manufacturer of rFVIIa or were co-authored by an
employee of Novo Nordisk. All therapeutic trials were supported
by the company or co-authored by an employee of Novo Nordisk.
Details are provided in the ’Characteristics of included studies’.
Risk of bias in included studies
Full details of quality assessments are presented in the ’Risk of bias’
table presented with each study in the ’Characteristics of included
studies’ table. Figure 2 and Figure 3 give visual representations of
the assessments of risk of bias across all studies and for each item
in the individual studies, respectively.
Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 3. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
14Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Prophylactic trials
All prophylactic studies had some threats to validity. For the most
part, these potential risks of bias were due to lack of detail provided
on the specific criteria and thus were judged as ’unclear’. Using
the Cochrane grading system:
• sequence generation was adequate in eight studies and
unclear in eight;
• allocation concealment was adequate in three studies and
unclear in 13;
• blinding of participants and personnel was adequate in nine
studies and unclear in seven;
• blinding of outcome assessment was adequate in nine
studies and unclear in seven;
• incomplete outcome data assessment was adequate in 13
studies and unclear in three;
• free of selective outcome reporting assessment was unclear
in all studies as study protocols were not available and none of the
studies were found to be registered with a clinical trials registry;
• free of other bias assessment was adequate in five studies,
unclear in 10 and inadequate in one. The study judged to be
inadequate in this category was Diprose 2005 in which there
were baseline differences between rFVIIa and placebo groups and
the study was underpowered; and
• power calculation was adequate in seven studies, unclear in
four and inadequate in five. The studies judged to be inadequate
had not performed power calculations.
Two prophylactic trials (Gill 2009; Lodge 2005a) had minimal
threats to validity.
Therapeutic trials
For therapeutic studies, the potential risks of bias were mostly due
to lack of detail provided on the specific criteria andwe thus judged
them as ’unclear’. Using the Cochrane grading system:
• sequence generation was adequate in seven studies and
unclear in six;
• allocation concealment was adequate in six studies and
unclear in seven;
• blinding of participants and personnel was adequate in 10
studies and unclear in three;
• blinding of outcome assessment was adequate in nine
studies and unclear in four;
• incomplete outcome data assessment was adequate in 11
studies and unclear in two;
• free of selective outcome reporting assessment was adequate
in seven studies (registered with a clinical trials registry), unclear
in four studies and inadequate in two studies. The two studies
judged to be inadequate were Boffard 2005a and Boffard 2005b
where emphasis was placed on the analysis where patients who
died within 48 hours were excluded and data for some outcomes
were presented for those patients alive at 48 hours;
• free of other bias assessment was adequate in two studies,
unclear in 10 and inadequate in one. The study judged to be
inadequate was Pihusch 2005 in which there were baseline
differences between rFVIIa and placebo groups;
• power calculation was adequate in eight studies, unclear in
one and inadequate in four studies where no power calculations
were performed.
All 13 RCTs using rFVIIa to treat established bleeding were re-
ported to be double-blind and placebo-controlled, but two (Bosch
2004; Bosch 2008) were felt to be largely free from threats to va-
lidity.
When compared to the prophylactic trials, the therapeutic trials
were less prone to bias, particularly in the areas of blinding and se-
lective reporting as judged by being registered clinical trials. Ther-
apeutic trials were also on average larger in sample size than pro-
phylactic trials.
Effects of interventions
See: Summary of findings for the main comparison
Prophylactic trials
Death
Mortality data were included for 15 trials. The individual re-
sults from all 15 studies had a 95% confidence interval (CI) that
included 1.0 (no difference between rFVIIa and placebo). The
pooled risk ratio (RR) was 1.04 (95% CI 0.55 to 1.97), I2 = 0%,
indicating that observed variation in the study results was compat-
ible with chance alone (Figure 4). In six studies (Ekert 2006; Essam
2007; Friederich 2003; Hanna 2010; Pugliese 2007; Raobaikady
2005) no deaths were mentioned; thus the number of deaths was
taken to be zero in all study arms. Control arm death rates were
generally low across all studies, themaximum being 1/10 (Diprose
2005).
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Figure 4. Forest plot of comparison: 1 rFVIIa used prophylactically versus placebo, outcome: 1.1 Death.
Blood loss
Ten studies contributed blood loss outcome data. The pooled
mean difference (MD) was -297 mL (297 mL less blood loss in
the rFVIIa arms) (95% CI -416 to -178) (Analysis 1.3). There was
marked variation in the amount of mean blood loss in the con-
trol arms, from 381 mL (Ma 2006) to 8552 mL (Lodge 2005b).
Five studies, each with fewer than 40 patients, had a 95% CI not
including zero favouring rFVIIa (Essam 2007; Friederich 2003;
Hanna 2010; Ma 2006; Pugliese 2007). These studies accounted
for 20% of the included patients in the analysis but their MDs
accounted for 82% of the pooled estimate.
Investigation of the heterogeneity is presented in Analysis 1.4.
Heterogeneity was explained in part by the size of the study.When
only studieswith greater than50patients (Gill 2009; Lodge 2005a;
Lodge 2005b; Sachs 2007) were included, the I2 = 0% and the
pooled MD was no longer statistically significant (MD -261 mL;
95% CI -550 to 28).
The pooled MD likely represents an overestimate of the effect of
rFVIIa as four additional studies, each with more than 40 patients,
reported no difference in blood loss and could not be incorpo-
rated into the pooled analysis because outcomes were not available
as mean/standard deviation (SD) (Ekert 2006; Planinsic 2005;
Raobaikady 2005; Shao 2006). The blood loss data were affected
by heavyweighting towards several small studies that reported very
precise estimation of blood losses.
Use of red cell transfusion
Twelve studies were included in the pooled analysis for red cell
transfusion requirements. The pooled MD was -261 mL (261
mL less red cells required in the rFVIIa arms) (95% CI -367 to -
154) (Figure 5). There was evidence of significant heterogeneity
(I2 = 62%). Data in units of red cells were converted to millilitres
assuming a single unit equated to 300 mL. There was marked
variation in the amount of mean red cell transfusion requirements
in the control arm, from 450 mL (Friederich 2003) to 5820 mL
(Johansson 2007). Six studies had a 95% CI not including zero
and favouring rFVIIa (Essam 2007; Friederich 2003;Hanna 2010;
Johansson 2007; Ma 2006; Pugliese 2007) and none had more
than 50 patients. Studies with fewer than 50 patients accounted
for 26% of the included patients in the analysis but their MDs
accounted for 81% of the pooled estimate.
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Figure 5. Forest plot of comparison: 1 rFVIIa used prophylactically versus placebo, outcome: 1.5 Red cell
transfusion requirements (mL).
Further investigation of the heterogeneity is presented in Analysis
1.6. Heterogeneity was explained in part by the size of the study.
When only studies with greater than 50 patients (Gill 2009; Lodge
2005a; Lodge 2005b; Planinsic 2005) were included, the I2 = 14%
and the pooled MD was no longer statistically significant (MD -
33 mL; 95% CI -260 to 193).
The pooled MD likely represents an overestimate of the effect of
rFVIIa as three additional studies reported no difference in red
cell requirements and could not be incorporated into the pooled
analysis because outcomes were not available as mean/SD (Ekert
2006; Raobaikady 2005; Shao 2006). The red cell transfusion
data was also affected by heavy weighting towards several small
studies that reported very precise estimation of red cell transfusion
requirements.
Number of patients transfused
Eight studies reported and contributed data on the number of
patients transfused. The pooled RR was 0.85 (95% CI 0.72 to
1.01) with marked heterogeneity present, I2 = 57% (Analysis 1.7).
Further exploration offered no clear explanation for heterogeneity
(Analysis 1.8). There was marked variation in the proportions of
patients receiving transfusions in the control arms, ranging from
37% (Lodge 2005a) to 100% (Lodge 2005b). Two studies had a
95% CI that did not include 1.0 (no difference) (Friederich 2003;
Lodge 2005b); both studies showed a reduction in the proportion
of people requiring transfusion with rFVIIa.
Thromboembolic events
Thirteen studies contributed data on thromboembolic events. The
pooled RR was 1.35 (95% CI 0.82 to 2.25) with heterogeneity
accounted for by chance alone (I2 = 0%) (Analysis 1.9). Control
event rates were generally low across all studies, the maximum
being 2/10 (Diprose 2005). Individually the 95% CIs of all the
included studies included 1.0 (no difference between rFVIIa and
placebo). Essam 2007 was not included in the pooled analysis as
no detail was provided on adverse events.
Therapeutic trials
Death
All included studies contributed data on death. The pooled RR
for overall mortality was 0.91 (95% CI 0.78 to 1.06) with no
statistical heterogeneity (I2 = 0%) (Figure 6). The mortality rates
in the control group varied from 0/9 (Chuansumrit 2005) to 22/
74 (30%) (Boffard 2005a). All studies yielded a RRwhose 95%CI
included 1.0 when examined in separate dose groups. However,
in Mayer 2005a the RR was 0.63 (95% CI 0.43 to 0.94).
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Figure 6. Forest plot of comparison: 2 rFVIIa used therapeutically versus placebo, outcome: 2.1 Death.
Control of bleeding
Seven trials reported outcome data on the control of bleeding, four
of which (Bosch 2004; Bosch 2008; Chuansumrit 2005; Pihusch
2005) provided data appropriate formeta-analysis. The pooledRR
was 0.95 (95% CI 0.88 to 1.03) in favour of rFVIIa, with I2 = 0%
(Analysis 2.3). The proportion of participants achieving bleeding
control in the placebo arm ranged from 44% (Chuansumrit 2005)
to 84% (Bosch 2004). For all the included studies, the RR 95%
CI included 1.0 (no difference).
The five intracranial haemorrhage (ICH) randomised controlled
trials (RCTs) (Mayer 2005a; Mayer 2005b; Mayer 2006; Mayer
2008; Narayan 2008) measured bleeding control in a different
way from the other studies. Although appropriate to the condition
they addressed, this meant that their results could not be com-
bined quantitatively. We thus considered the additional insights
they provided qualitatively alongside the above pooled RR. In the
initial efficacy study (Mayer 2005a), the trial authors reported a
statistically significant reduction in the growth of haemorrhage
volume in favour of rFVIIa. Additional data provided suggested
that reductions in the increase in haemorrhage volume attributable
to rFVIIa were associated with reduced disability as measured by
the Modified Rankin Scale, the Extended Glasgow Coma Scale,
the Barthel Index and the National Institutes of Health Stroke
Scale at 90 days. The second efficacy trial (Mayer 2008) defined
its primary endpoint as severe disability or death by a Modified
Rankin scale score of 5 or 6. Although this study did show a sig-
nificant reduction in growth of volume of haemorrhage in the 80
µg/kg rFVIIa group, there was no significant difference in the pri-
mary endpoint at 90 days. None of the safety trials (Mayer 2005b;
Mayer 2006; Narayan 2008) showed a significant reduction in
their secondary endpoints of growth of volume of haemorrhage.
Use of red cell transfusion
Five studies contributed data on the use of red cell transfusions
(Bosch 2004; Bosch 2008; Chuansumrit 2005; Hauser 2010a;
Hauser 2010b). The pooled MD was -89 mL (95% CI -264
to 87) with minimal heterogeneity (I2 = 16%) (Figure 7). The
use of transfusion in the control groups varied from 103 mL
(Chuansumrit 2005) to 2730 mL (Hauser 2010a). The 95% CI
for the MD for all the included studies included zero (no differ-
ence).
18Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 7. Forest plot of comparison: 2 rFVIIa used therapeutically versus placebo, outcome: 2.5 Red cell
transfusion requirements (mL).
Data from Boffard 2005a and Boffard 2005b were reported as
median/range, therefore these could not be incorporated into the
pooled analysis. The exclusion of these studies is unlikely to change
the pooledMDas therewas no significant difference in the primary
endpoint of number of red cell units transfused for all patients at
48 hours.
Number of patients transfused
Three of the 13 studies investigating the use of rFVIIa for treating
bleeding collected information on the number of patients trans-
fused (Chuansumrit 2005; Hauser 2010a; Hauser 2010b). These
studies showed a trend to a lower number of transfused patients
in the rFVIIa treatment groups (RR 0.94; 95% CI 0.89 to 1.00)
(Analysis 2.7).
Thromboembolic events
All of the treatment trials contributed data on thromboembolic
events. The pooled RR was 1.14 (95% CI 0.89 to 1.47) with
no heterogeneity beyond chance expectation (I2 = 0%) (Analysis
2.8). Control event rates were generally low across all studies, the
maximum being 3/8 (Mayer 2006). Individually the 95% CIs of
all the included studies included 1.0 (no difference between rFVIIa
and placebo).
Thromboembolic events across all RCTs
Twenty-six studies were available from prophylactic and therapeu-
tic study groups to contribute to an overall combined estimate
of the risk of thromboembolic events. The pooled RR was 1.18
(95% CI 0.94 to 1.48) with no observed heterogeneity (I2 = 0%)
(Figure 8). When considered as individual outcomes, there was
no difference in cardiovascular, stroke or venous events. However,
there was a significant increase in arterial thromboembolic events
(RR 1.45; 95% CI 1.02 to 2.05) (Figure 9).
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Figure 8. Forest plot of comparison: 3 rFVIIa used prophylactically or therapeutically versus placebo
(adverse events), outcome: 3.1 Total thromboembolic events.
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Figure 9. Forest plot of comparison: 3 rFVIIa used prophylactically or therapeutically versus placebo
(adverse events), outcome: 3.4 Total arterial events.
Publication bias
We assessed publication bias for each of the outcomes above. In the
prophylactic studies, there was little or no asymmetry except for
the outcome number of patients transfused. The funnel plot for
the analysis number of patients transfused suggested that theremay
be small missing studies with RR > 1.0 (favouring placebo) (Figure
10). In the therapeutic studies, there was no marked asymmetry
in the funnel plots.
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Figure 10. Funnel plot of comparison: 1 rFVIIa used prophylactically versus placebo, outcome: 1.7 Numbers
of patients transfused.
As noted in the methods section, we did review ongoing studies
from our previous update. There has been no reported progress
in ongoing studies since the last review despite adequate time for
recruitment. This may also be a potential source of publication
bias.
How does this update differ from the previous review?
Results: potential benefits of rFVIIa
There was no evidence of a significant mortality benefit with the
use of rFVIIa. This finding remains unchanged compared to the
previous version of this review (Lin 2011), despite the addition
of recent RCTs. In this updated version of the review, the risk of
mortality associated with the prophylactic use of rFVIIa changed
from a RR of 1.06 (95%CI 0.50 to 2.24) to a RR of 1.04 (95%CI
0.55 to 1.97). For therapeutic studies, the trend towards decreased
mortality in the previous Cochrane review with a RR of 0.89 (95%
CI 0.77 to 1.03) is similar to the current review with a RR of
0.92 (95% CI 0.79 to 1.08). Looking at the individual studies,
Mayer 2005a was the only study that showed a mortality benefit
and in this study, mortality was a secondary outcome. The sub-
sequent phase III clinical trial in spontaneous ICH (Mayer 2008)
was unable to show an improvement in survival or functional out-
come, even though a reduction in haematoma growth was seen.
The group receiving 80 µg/kg rFVIIa was found to have a more
frequent rate of arterial events when compared to placebo. The
question as to whether there may be clinical benefit in a subgroup
of high-risk patients with spontaneous ICH is being addressed in
two registered clinical trials which, at the time of writing, have just
begun recruiting (Flaherty 2008; Gladstone 2011).
As in the previous Cochrane review (Lin 2011), the volume of
perioperative blood loss and red cell transfusions for the prophy-
lactic trials remained statistically significant in favour of rFVIIa.
However, there was evidence of important statistical heterogeneity
for these studies.
In this version, although not statistically significant, there is a trend
towards a lower number of patients transfused favouring rFVIIa
in the included eight prophylactic trials (RR 0.85; 95% CI 0.72
to 1.01) and three therapeutic trials (RR 0.94; 95% CI 0.89 to
1.00) compared to the previous version (prophylactic RR 0.91;
95% CI 0.82 to 1.02 and therapeutic RR 0.94; 95% CI 0.29 to
3.04). For the prophylactic estimate, potential publication bias
may overestimate the benefit of rFVIIa.
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Results: potential risks of rFVIIa
In this review, thromboembolic events were not statistically in-
creased in prophylactic (RR 1.35; 95% CI 0.82 to 2.25) or ther-
apeutic (RR 1.14; 95% CI 0.89 to 1.47) studies. Pooling adverse
events across both prophylactic and therapeutic studies did lead
to an increase in arterial thromboembolic events (RR 1.45; 95%
CI 1.02 to 2.05) (Figure 9), which is a new finding compared to
the previous version.
D I S C U S S I O N
Summary of main results
Sixteen trials including a total of 1361 participants examined the
use of rFVIIa prophylactically to prevent bleeding. The studies
were conducted in a range of clinical situations including cardiac
surgery; liver biopsy; partial hepatectomy; liver transplantation;
prostatectomy; burns excision; pelvic reconstruction; craniofacial
reconstruction and spinal surgery. The main outcomes were mor-
tality, blood loss, red cell transfusion requirements, numbers trans-
fused and thromboembolic adverse events. All studies were ran-
domised controlled trials (RCTs), but many were prone to bias,
particularly through lack of clarity about how participants were
randomised. There was no effect on mortality (risk ratio (RR)
1.04; 95% confidence interval (CI) 0.55 to 1.97). Modest benefits
were found in the outcomes of blood loss and red cell transfu-
sion requirements (less than one red cell unit saved with rFVIIa
treatment); however, these favourable findings were likely overesti-
mated because data were not available from larger negative studies
for inclusion in the meta-analysis. A statistically non-significant
trend towards an increased risk of thromboembolic events with
rFVIIa was also observed (see ’Summary of findings for the main
comparison’).
Thirteen trials including a total of 2929 participants examined
the therapeutic role of rFVIIa for the treatment of bleeding. Again
the studies were conducted in a range of different clinical sce-
narios including blunt and penetrating trauma; gastrointestinal
haemorrhage; Dengue haemorrhagic fever; intracranial haemor-
rhage (ICH) and stem cell transplantation. There was no differ-
ence in the outcomes ofmortality (RR0.91; 95%CI 0.78 to 1.06),
control of bleeding, red cell transfusion requirements, numbers
transfused and thromboembolic adverse events. All studies were
placebo-controlled, double-blind RCTs. Two trials (Bosch 2004;
Bosch 2008) were substantially free from bias; the remainder had
threats, particularly lack of detail about randomisation. None of
the pooled outcomes showed reliable evidence of an advantage (or
disadvantage in the case of adverse events) of rFVIIa over placebo.
However, there were trends towards decreasedmortality, decreased
number of patients transfused and increased thromboembolic ad-
verse events with rFVIIa treatment (see ’Summary of findings for
the main comparison’).
Although there were no differences seen in the total thromboem-
bolic adverse events, when arterial thrombotic events were con-
sidered for all studies combined, a statistically significant increase
was observed (RR 1.45; 95% CI 1.02 to 2.05).
Quality of the evidence
Issues relating tomethodological quality of the trials have been de-
scribed in the ’Risk of bias’ figures (Figure 2 and Figure 3). Over-
all, all studies except four (Bosch 2004; Bosch 2008; Gill 2009;
Lodge 2005a) had threats to validity. In most cases, the threats
to validity were assessed as ’unclear’ because details were not pro-
vided in the publications. Many of the studies, in particular the
prophylactic studies, were also hampered by inadequate power due
to small sample size. The clinical settings in which more than one
adequately powered trial was conducted included trauma, partial
hepatectomy, liver transplantation, cirrhosis with upper gastroin-
testinal bleeding and spontaneous intracranial haemorrhage.
Potential biases in the review process
Concerning the validity of the findings of this systematic review,
there are limitations. We were unable to obtain data from all au-
thors to be used quantitatively in the meta-analysis and often the
excluded studies were those that did not favour rFVIIa (specifically
in the prophylactic trials, four RCTs in the outcome of total blood
loss and three RCTs in the outcome of red cell transfusion require-
ments showed no difference between rFVIIa and placebo). In the
therapeutic studies for the outcome control of bleeding, data from
the intracranial haemorrhage studies could not be included in the
pooled estimate because they expressed their results in a different
manner (appropriately) from other therapeutic RCTs and so were
considered qualitatively.
Publication bias remains possible. We examined funnel plots and
detected publication bias in the outcome of number of patients
transfused in the prophylactic RCTs where there were a lack of
studies that favoured placebo over rFVIIa treatment. A potentially
more significant source of publication bias was our inability to
include unpublished but ongoing trials that have not been com-
pleted since the last version of this review.
Agreements and disagreements with other
studies or reviews
The findings of this updated review extend and are consistent
with other published meta-analyses. The relevant Cochrane sys-
tematic reviews include Marti-Carvajal 2007 and You 2006.
Marti-Carvajal 2007 examined upper gastrointestinal bleeding
(UGIB) in patients with liver disease but at the time of the re-
view, the only RCT included was Bosch 2004. You 2006 consid-
ered haemostatic drugs for intracranial haemorrhage (ICH) and
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included the first three RCTs of rFVIIa in ICH (Mayer 2005a;
Mayer 2005b;Mayer 2006) but notMayer 2008. Themeta-analy-
sis showed reduction in risk of disability and death by themodified
Rankin scale score but this was not consistent when an alternative
outcome score (extended Glasgow Outcome Scale) was used. The
use of rFVIIa was also balanced against a trend towards increased
thromboembolic events. Ranucci 2008 performed a meta-analysis
of rFVIIa in major surgical procedures and included seven of the
prophylactic studies included in this review. They found a signifi-
cant reduction in the risk of receiving allogeneic packed red blood
cells (odds ratio (OR) 0.29; 95% CI 0.10 to 0.80) although the
absolute amount of red cell transfusion received was not analysed.
Estimates of mortality and thromboembolic events were similar
to the estimates in this review for prophylactic studies.
A recent systematic review published by Hsia 2008 reported sim-
ilar estimates for mortality (OR 0.88; 95% CI 0.71 to 1.09) and
thromboembolic events (OR 1.17; 95% CI 0.87 to 1.58). Hsia
2008 also found that rFVIIa reduced the number of patients re-
quiring additional red blood cell transfusion (OR 0.54; 95%CI
0.34 to 0.86). In our current review, the absolute amount of red
cell transfusion has been quantified; at least in the prophylactic
setting, the estimated absolute amount of total blood loss or red
cell transfusion requirement saved with rFVIIa treatment was less
than one unit of red blood cells (RBCs) (the assumption in this
review was that one red cell unit was equivalent to 300 mL). How-
ever, this was likely to be an overestimate of the effect as data from
negative studies could not be incorporated into the pooled anal-
yses as described earlier in the results. In the therapeutic setting,
Hsia 2008 identified one study (Boffard 2005a) of four included
RCTs favouring rFVIIa for the outcome of additional red blood
cell transfusion. The numbers used in the meta-analysis and re-
ported in Boffard 2005a for this outcome were based on the per-
centage of patients alive at 48 hours receiving massive transfusion
(more than 20 units of RBCs). The number of patients requir-
ing massive transfusion for all patients was not provided in the
publication. Thus, although there may be an advantage to rFVIIa
in decreasing blood loss and red cell transfusion requirements, we
believe that this advantage is small when the limitations of the data
and the absolute amount of blood saved are considered.
In line with the findings of our Cochrane review, a recent meta-
analysis of the off-label use of rFVIIa in cardiac surgery, liver trans-
plantation, intracranial haemorrhage, trauma and prostatectomy
showed no mortality benefit among patients who received rFVIIa
(Yank 2011). In this review, the administration of rFVIIa was re-
ported to increase the risk of arterial thromboembolism among
patients with intracranial haemorrhage (risk difference (RD) 0.03;
95% CI 0.01 to 0.06 and RD 0.06; 95% CI 0.01 to 0.11 for
medium- and high-dose rFVIIa, respectively) and the rate of all
thromboembolic events among cardiac surgery patients (RD 0.05;
95% CI 0.01 to 0.10). Unlike previous studies of the off-label
use of rFVIIa, Yank 2011 also reported a decreased risk of acute
respiratory distress syndrome among body trauma patients who
received rFVIIa (RD -0.05; 95% CI -0.02 to -0.08).
More recently, Levi 2010 reported on the risks related to rFVIIa
use, by analysis of data held by Novo Nordisk. The authors re-
ported that individuals who received rFVIIa experienced a higher
frequency of arterial thromboembolic events when compared to
patients who were given placebo (5.5% versus 3.2%, P = 0.003).
This association was more pronounced among older patients over
the ages of 65 years (rFVIIa: 9.0%versus placebo: 3.8%, P= 0.003)
and 75 years (rFVIIa: 10.8% versus placebo: 4.1%, P = 0.02). In
the Levi 2010 study, there was no significant difference in the rates
of venous thromboembolism among patients who received rFVIIa
as compared to those who received placebo (5.3% versus 5.7%).
How do the conclusions of this update differ from the
previous review?
This review provides the most up to date assessment of the effec-
tiveness and safety of RFVIIa. With the addition of four RCTs,
there was a significant increase in the number of arterial throm-
boembolic events observed among patients who received rFVIIa.
Despite the greater number of trials, almost all of the findings in
support of and against the use of rFVIIa could be due to chance, in-
dicating ongoinguncertainty about the true effectiveness of rFVIIa
in patients without haemophilia. Suggestions of a potential benefit
of rFVIIa reside in the findings of decreased blood loss and red cell
transfusion requirements and a trend towards a decreased number
of patients who required blood transfusion and decreased mortal-
ity in the therapeutic setting. However, the findings of decreased
blood loss and red cell transfusion in this review were modest and
are likely overestimates of the true benefit of rFVIIa. There may
be publication bias particularly in the number of patients trans-
fused overestimating the benefit of rFVIIa, which has been found
in other reviews (Hsia 2008; Ranucci 2008). Moreover, in direct
(and even some indirect) comparisons of dose of rFVIIa, there was
no evidence of a dose-response effect.
Any (small) benefits of rFVIIa are likely to be offset by its potential
thromboembolic risks. These risks are likely to be underestimated
and may be more serious and/or frequent in the real world than in
the RCT setting when tight inclusion criteria apply. For many of
the patients in the clinical settings of the included studies, a higher
risk of thrombosis might be expected, for example, related to im-
mobilisation and stroke. In addition, a history of thrombosis or
vaso-occlusive disease was a criterion for exclusion in most of the
included studies and active surveillance (e.g. scheduled lower ex-
tremity ultrasounds or troponin measurements) for adverse events
was reported in only 11 of 29 trials. These greater risks are consis-
tent with the analysis of passive surveillance of reports describing
thromboembolic events for the Food and Drug Administration
Adverse Reporting System, which indicated that many events fol-
lowing rFVIIa use occurred after unlabelled indications and often
resulted in serious morbidity and mortality (O’Connell 2006).
Although a large, adequately powered trial with a strict transfu-
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sion protocol and active surveillance for adverse events could be
designed to address with greater precision the effect size for use
of rFVIIa, the results of this review perhaps question the need for
such a trial. It seems unlikely that a large benefit for the drug exists
based on the findings of 29 trials, and for those trials which ini-
tially found evidence of benefit, larger follow-up studies have not
confirmed these earlier promising results. This has occurred in the
setting of cirrhosis with UGIB where potential benefit in a sub-
group of high-risk patients (Bosch 2004) was not confirmed in the
RCT looking specifically at this high-risk subgroup (Bosch 2008).
In the setting of spontaneous intracranial haemorrhage (ICH),
the earlier trial showed benefit in a secondary outcome of disabil-
ity and death (Mayer 2005a), however this was not borne out in
the phase III RCT designed with a primary outcome of disability
and death (Mayer 2008). The phase III trial in trauma patients
(Hauser 2010a; Hauser 2010b) was terminated early due to a low
likelihood of reaching a positive outcome, again not confirming
potential benefits seen in the earlier trauma trials (Boffard 2005a;
Boffard 2005b).
It is difficult to highlight specific gaps or areas where new RCTs
are required now. Although there have been retrospective obser-
vational studies supporting the use of rFVIIa in refractory bleed-
ing, such as in the setting of cardiac surgery, these studies are lim-
ited by the lack of a control group, lack of transfusion protocols
and observer bias. Without performing large RCTs, one cannot
exclude an effect of rFVIIa, particularly if compared to the use
of another haemostatic agent such as tranexamic acid (which has
demonstrated a safer risk profile) or fibrinogen concentrate or even
more platelet transfusions in the post-cardiac bypass setting. In
these situations, the immediate real risk of life-threatening ongo-
ing haemorrhage is being weighed by clinicians against a poten-
tial risk of no benefit from rFVIIa or potential thrombotic harm.
These related issues of prescribing behaviour have also been re-
cently summarised by Lipworth 2012.
In summary, the aim of this review was to update the assessment of
the effectiveness and safety of rFVIIa in the management of bleed-
ing in patients without haemophilia. We conclude that the clinical
value of rFVIIa as a more general haemostatic drug, both as pro-
phylaxis in high blood loss surgery and as therapy to treat uncon-
trollable bleeding, remains unproven. In addition, its use is asso-
ciated with an increased risk of adverse arterial thrombotic events.
Based on the available RCT data, there is little evidence of benefit
for the use of off-label rFVIIa in patients without haemophilia.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Unrestricted, unevaluated administration of rFVIIa outside li-
censed uses is not justified on the basis of the randomised con-
trolled trials (RCTs) identified and analysed in this review. Admin-
istration of rFVIIa outside its current license should be restricted
to rigorous research studies and clinical trials, planned to add to
existing knowledge in a systematic way.
Implications for research
The results of ongoing research should be actively monitored and
systematically reviewed independently of the pharmaceutical com-
panies with a financial interest in this drug. Any future RCTs
should be adequately powered, focusing on clinical outcomes such
as mortality, rather than blood loss and transfusion use. Continu-
ing close attention to measurement of adverse, particularly throm-
boembolic, events is required.
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∗ Indicates the major publication for the study
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Boffard 2005a
Methods Double-blind, placebo-controlled RCT
Participants Adults
Severely bleeding blunt trauma
Group 1 blunt = 69 (numbers eligible for analysis)
Group 2 blunt = 74
Randomised but not given the allocated treatment = 15
All blunt = 158
Interventions Group 1. 3 doses of iv rFVIIa. 200 µg/kg first dose, after 8 units of RBC transfused; 100
µg/kg 1 hour after dose 1; 100 µg/kg 3 hours after dose 1. Total dose 400 µg/kg.
Group 2. Placebo given at each of the 3 time points.
Outcomes 1. (Primary) RBCs transfused in 48 hours after first dose FVIIa/placebo
2. Other transfused products in first 48 hours
3. Mortality (and a composite endpoint of death and critical complications)
4. Days on ventilator
5. Days on ICU
6. Adverse events
Sources of Support Study supported by Novo Nordisk. One author from Novo Nordisk. 4 authors received
consultancy fees from Novo Nordisk
Notes Important threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blind, but no detail
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated to be double-blind, but no detail
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Boffard 2005a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up: 22; 14%
Selective reporting (reporting bias) High risk Emphasis on analysiswhere patientswhodied
within 48 hours were excluded. For number
of patients requiringmassive transfusion, data
for all patients at 48 hours were not presented
Other bias Unclear risk Lack of clarity about flow of patients and ap-
propriateness of denominators used in anal-
ysis. Equality of distribution of patients be-
tween the 32 contributing study centres. No
transfusion guidelines provided
Power calculation? Low risk Done; target 140 (achieved)
Boffard 2005b
Methods Double-blind, placebo-controlled RCT
Participants Adults
Severely bleeding penetrating trauma
Group 1 penetrating = 70
Group 2 penetrating = 64
Randomised but not given an allocated treatment = 9
All penetrating = 143
Interventions Group 1. 3 doses of iv rFVIIa. 200 µg/kg first dose, after 8 units of RBC transfused; 100
µg/kg 1 hour after dose 1; 100 µg/kg 3 hours after dose 1. Total dose 400 µg/kg.
Group 2. Placebo given at each of the 3 time points.
Outcomes 1. (Primary) RBC transfused in 48 hours after first dose FVIIa/placebo
2. Other transfused products in first 48 hours
3. Mortality
4. Days on ventilator
5. Days on ICU
Sources of Support Study supported by Novo Nordisk. One author from Novo Nordisk. 4 authors received
consultancy fees from Novo Nordisk
Notes Important threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
32Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Boffard 2005b (Continued)
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blind, but no detail
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated to be double-blind, but no detail
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 13; 9%
Selective reporting (reporting bias) High risk Emphasis on analysiswhere patientswhodied
within 48 hours were excluded. For number
of patients requiringmassive transfusion, data
for all patients at 48 hours were not presented
Other bias Unclear risk Lack of clarity about flow of patients and ap-
propriateness of denominators used in anal-
ysis. Equality of distribution of patients be-
tween the 32 contributing study centres. No
transfusion guidelines provided
Power calculation? Low risk Done; target 140 (achieved)
Bosch 2004
Methods Double-blind, placebo-controlled RCT
Participants Adults
Upper gastrointestinal haemorrhage in patients with cirrhosis
Group 1 = 121
Group 2 = 121
Randomised but not given allocated treatment = 3
All randomised = 245
Interventions Group 1. 8 x 100 µg/kg doses of iv rFVIIa. Initial dose given at time = 0, which was
within 6 hours of bleed/admission. Subsequent doses given at 0, 2, 4, 6, 12, 18, 24, 30
hours. Total dose 800 µg/kg.
Group 2. Placebo at same times.
Outcomes 1. (Primary) Control of acute bleeding within 5 days OR failure to prevent rebleeding
between 24 hours and 5 days or death during first 5 days
2. Control of acute bleeding independently
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Bosch 2004 (Continued)
3. Prevention of rebleeding independently
4. Active bleeding at first endoscopy
5. 5-day mortality
6. 6-week mortality
7. Transfusion requirements
8. Number of emergency and elective procedures performed
9. Length of stay on intensive care or hospital
10. Frequency of adverse events including thromboembolic events
11. Changes in coagulation related parameters
12. Other haematology and biochemical parameters
Sources of Support Study supported by Novo Nordisk. Trial planning and steering committee contained
Novo Nordisk employees. 2 authors from Novo Nordisk
Notes Minimal threats to validity (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated. Stratified by trial cen-
tre. Central interactive voice response system
Allocation concealment (selection bias) Low risk Treatment allocation in sealed envelopes dur-
ing study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double-blind. Indicated placebo
was identical
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated to be double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 8; 3%
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Low risk -
Power calculation? Low risk Done; target 240 (achieved)
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Bosch 2008
Methods Double-blind, placebo-controlled RCT
Participants Adults
Upper gastrointestinal haemorrhage in patients with cirrhosis
Group 1 = 85
Group 2 = 85
Group 3 = 86
Randomised but not given an allocated treatment = 9
Total randomised = 265
Interventions Group 1. First dose 200 µg/kg rFVIIa iv followed by doses of 100 µg/kg at 2, 8, 14 and
20 hours after initial dose. Total dose 600 µg/kg
Group 2. First dose 200 µg/kg rFVIIa iv followed by second dose of 100 µg/kg at 2
hours and placebo at 8, 14 and 20 hours after initial dose. Total dose 300 µg/kg
Group 3. Placebo at same times.
Outcomes 1. (Primary) Treatment failure defined as: failure to control acute bleeding within 24
hours OR failure to prevent rebleeding OR death within 5 days
2. 5-day and 42-day mortality
3. Failure to control 5-day bleeding
4. Failure to control bleeding within 24 hours
5. Failure to prevent rebleeding at 5 days
6. Number of emergency procedures performed within 5 days
7. Transfusion requirements at 24 hours and 5 days
8. Frequency of adverse events up to 42 days
9. Changes in coagulation related parameters
Sources of Support Study supported by Novo Nordisk. Sponsor designed study, analysed data and assisted
in preparation of manuscript
Notes Minimal threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was computer-generated and
stratified by centre with equal allocation be-
tween groups. Central interactive voice-re-
sponse system
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double-blind. Active agent and
placebo were provided as indistinguishable
powders for reconstitution
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Bosch 2008 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated to be double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 9; 3%
Selective reporting (reporting bias) Low risk Registered at www.clinicaltrials.gov
Other bias Unclear risk Undesired selection bias occurred in several
centres, whereby patients with a better prog-
nosis were over-represented
Power calculation? Low risk Done; target 258 (not achieved)
Chuansumrit 2005
Methods Double-blind, placebo-controlled RCT
Participants Children
Dengue haemorrhagic fever
Group 1 = 18
Group 2 = 10
Interventions Group 1. 1 dose of 100 µg/kg of iv rFVIIa. Further dose allowed after 30 minutes if
bleeding not controlled. Total dose 100 to 200 µg/kg.
Group 2. Placebo given in same manner.
Outcomes 1. Assessment of bleeding control 0.25, 0.5, 0.75, 1, 2, 6, 12, 24 hours after first dose
of allocated treatment
2. Blood component requirements
3. Laboratory investigations
No primary outcome defined
Sources of Support Study supported by Novo Nordisk. One author from Novo Nordisk
Notes Important threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk No details given
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Chuansumrit 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double-blind. Indicated that
placebo was identical
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated to be double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up: 3; 11%
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Unclear risk Small study size. Equality of distribution of
patients between the 5 contributing study
centres. No specific transfusion guidelines
provided
Power calculation? High risk No power calculation
Diprose 2005
Methods Double-blind, placebo-controlled RCT
Participants Adults
Complex non-coronary cardiac surgery requiring cardio-pulmonary bypass
Group 1 = 10
Group 2 = 10
Total randomised = 20
Interventions Group 1. 1 dose of 90 µg/kg rFVIIa iv after bypass and reversal of heparin.
Group 2. Placebo; equivalent volume of 0.9% saline.
Outcomes 1. (Primary) The number of patients receiving any allogeneic transfusion
2. Total units of red cells and coagulation products transfused
3. Adverse events
4. Also reported length of stay in intensive care and hospital
Sources of Support 2 authors had consulted forNovoNordisk. The company had no role in design, execution
or interpretation of the study
Notes Important threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
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Diprose 2005 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double-blind (investigators, pa-
tients, and all involved in patient care). All
study agents identified, prepared and blinded
by pharmacy staff. Placebo was equal volume
of saline
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated to be double-blind (investigators, pa-
tients and all involved in patient care)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 0; 0%
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias High risk Difference in baseline characteristics. Small
study which was underpowered
Power calculation? Low risk Done; target 64 (not achieved)
Ekert 2006
Methods Double-blind, placebo-controlled RCT
Participants Infants less than 1 year of age
Congenital heart disease requiring cardio-pulmonary bypass
Group 1 = 40
Group 2 = 36
Randomised but not given an allocated treatment = 6
Total randomised = 82
Interventions Group 1. First dose of 40 µg/kg rFVIIa iv after bypass and reversal of heparin; second
dose if excessive bleeding at 20 minutes post-reversal of heparin; third dose if delayed
postoperative bleeding in the post-surgery recovery period. All participants had 1 or 2
doses. Total dose 40 to 80 µg/kg
Group 2. Placebo, freeze-dried powder for reconstitution, as for group 1
Outcomes 1. (Primary) Time to chest closure after reversal of heparin
2. Units/volume of platelets, FFP and blood transfused in the first 48 to 72 hours
3. Blood loss in the first 12 hours
Sources of Support Novo Nordisk supplied study agent and placebo but no other stated involvement
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Ekert 2006 (Continued)
Notes Some threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double-blind. Indicated that
placebo identical. For primary outcome, op-
erating team was unaware of results of pro-
thrombin time until patient in intensive care
unit after chest closure
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated to be double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 1; 1%
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Low risk -
Power calculation? High risk No power calculation
Essam 2007
Methods RCT
Participants Adults
Elective cardiac revascularisation requiring cardio-pulmonary bypass
Group 1 = 15
Group 2 = 15
Total randomised = 30
Interventions Group 1. 1 dose of 90 µg/kg rFVIIa iv after bypass and reversal of heparin. Group 2. No
rFVIIa
Outcomes 1. Chest tube drainage during first 24 hours after surgery
2. Blood products transfused during first 24 hours after surgery
3. Serial haematological parameters during first 24 hours after surgery including haemo-
globin, INR, PTT, fibrinogen
39Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Essam 2007 (Continued)
Sources of Support No statement made
Notes Important threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk Randomisation was established through sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details given on whether a placebo was given or on outcome
assessment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details given on whether a placebo was given or on outcome
assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 0; 0%
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Unclear risk Conclusion overstated for small study size
Power calculation? High risk No power calculation
Friederich 2003
Methods Double-blind, placebo-controlled RCT
Participants Adults
Retropubic prostatectomy
Group 1 = 8
Group 2 = 16
Group 3 =12
Total randomised = 36
Interventions Group 1. 1 dose of 20 µg/kg rFVIIa iv in early operative phase.
Group 2. 1 dose of 40 µg/kg rFVIIa iv at same time.
Group 3. Placebo, saline, at same time.
Outcomes 1. (Primary) Total of pre-operative blood loss up to 24 hours after surgery
2. (Co-primary) Transfusion requirements
3. Adverse effects, including thromboembolic events
40Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Friederich 2003 (Continued)
4. Duration of operation and length of hospital stay were also reported
Sources of Support Novo Nordisk supplied study agent and placebo but no other stated involvement
Notes Some threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by a computer-generated
scheme
Allocation concealment (selection bias) Low risk Statement that treatment allocation con-
cealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double-blind. Active agent and
placebo (saline) were provided as indistin-
guishable solutions
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated to be double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 0; 0%
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Unclear risk Small study size
Power calculation? Unclear risk Done; target not stated
Gill 2009
Methods Multicentre, double-blind, placebo-controlled RCT
Participants Adult patients undergoing cardiac surgery requiringCPB and admitted to a postoperative
care environment for at least 30 minutes - randomised on reaching prespecified bleeding
rate
Group 1 = 35
Group 2 = 69
Group 3 = 68
Randomised but not given the allocated treatment = 7
Total randomised = 179
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Gill 2009 (Continued)
Interventions Group 1 = rFVIIa 40 µg/kg
Group 2 = rFVIIa 80 µg/kg
Group 3 = Placebo
Outcomes 1. (Primary) Critical serious adverse events (death, cerebral infarction, myocardial in-
farction, pulmonary embolism and other thromboembolic events)
2. Rates of reoperation within 30 days after rebleeding
3. Transfusion of allogeneic blood and blood products within 5 days after trial drug
administration
4. Drainage volumes from cardiothoracic cavity within 4 hours, 24 hours and 5 days
after trial drug administration
Sources of Support 2 authors from Novo Nordisk
Sponsor responsible for trial operations and statistical analyses
Notes Protocol for the use of antifibrinolytics was unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised through interactive voice re-
sponse system and were always assigned to
the lowest available randomisation number
Allocation concealment (selection bias) Low risk Masking of treatment allocation main-
tained until all patient data entered and
database locked
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Physical appearances of placebo and rFVIIa
were identical
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Described as double-blind. Masking of
treatment allocation maintained until all
patient data entered and database locked
Incomplete outcome data (attrition bias)
All outcomes
Low risk No patients were lost to follow-up
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Unclear risk No protocol provided for the use of antifib-
rinolytic therapy
Power calculation? Low risk Based on both safety (based on probability
that uneven distribution of critical serious
adverse events between rFVIIa and placebo
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Gill 2009 (Continued)
groups would be minimised) and efficacy
evaluation to detect a 35% reduction in
need for any allogeneic transfusions on the
highest cohort
Hanna 2010
Methods Single-centre, placebo-controlled RCT
Participants Paediatric patients of ASA class I and II with congenital craniofacial malformation sched-
uled to undergo reconstructive surgery
Group 1 = 15
Group 2 = 15
Group 3 = 15
Total randomised = 45
Interventions Group 1 = Control. No medications.
Group 1 = Tranexamic acid at hour 0, tranexamic acid 100 mg/kg over 15 minutes and
then maintenance infusion of 1 mg/kg/h until skin closure
Group 3 = rFVIIa at hour 0, rFVIIa 10 µg/kg over 15 minutes and then maintenance
infusion of 10 µg/kg/h until skin closure
Outcomes 1. Perioperative and intraoperative blood loss
2. Transfusion requirements at 24 h and 48 hours from treatment
3. Serial measurements for platelet count, fibrinogen concentration and FDPs prior to
surgery (hour 0), 1 hour and 12 hours following completion of surgery
4. Serial haemoglobin levels were measured hourly
Sources of Support No statement made
Notes Some threats to validity were identified (See ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk Study described as “double-blind”, and the
control arm as “placebo”. Each patient re-
ceived a small bag with 2 syringes - for initial
dose and maintenance dose. No details pro-
vided about whether the formulations looked
the same or if the clinical team was blinded
Blinding of participants and personnel
(performance bias)
Unclear risk No details given
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Hanna 2010 (Continued)
All outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details given
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details given
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Unclear risk Small sample size
Power calculation? Unclear risk No details were provided
Hauser 2010a
Methods Multi-centre, double-blind, placebo-controlled RCT
Participants Adult patients who had sustained blunt trauma and who had received a minimum of 4
units of red blood cells (RBCs) but had not yet completed an 8th unit within 12 hours
of injury
Group 1 = 221
Group 2 = 247
Randomised but not given the allocated treatment = 13
Total randomised = 481
Interventions Group 1. 3 doses of iv rFVIIa. 200 µg/kg first dose, after 8 units of RBC transfused; 100
µg/kg 1 hour after dose 1; 100 µg/kg 3 hours after dose 1. Total dose 400 µg/kg.
Group 2. Placebo given at each of the 3 time points.
Outcomes Primary:
1. 1st tier endpoint was superiority in all-cause 30-day mortality in blunt trauma
2. If not met, the 2nd tier primary conditional endpoint of non-inferiority of mortality
and superiority on durable morbidity (pulmonary and/or renal dysfunction at day 30)
was applied
Secondary:
3. Transfused units of RBC, plasma, platelets, cryoprecipitate, fibrinogen concentrate
and all allogeneic blood products at 24 hours and 48 hours after dosing and number of
patients requiring massive RBC transfusion (≥ 10 units of RBC) at 24 hours
4. Number of patients with thromboembolic events, multiple organ failure (MOF),
single organ failure (SOF) and days alive and free from MOF, SOF, intensive care unit,
hospital or ventilator, and/or renal replacement therapy, through day 30
Sources of Support Drug supplied by sponsor: Novo Nordisk
Sponsor responsible for data management, assisted with trial design
Analyses performed by sponsor but also repeated by independent statistician and the
latter is presented in the article
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Hauser 2010a (Continued)
Notes Inaccurate denominators were used although intention-to-treat analysis was supposed
to have been performed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation in random permuted
blocks with allocation of every randomisa-
tion block to a specific centre. Randomisa-
tion was confirmed through an interactive
voice response system set up by the sponsor
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Description of placebo as the same formu-
lation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk FFP differences may have been due to
changes in INR, the results of which would
have been available to clinicians and the
transfusion protocol was based on INR re-
sults
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis was performed
Selective reporting (reporting bias) Unclear risk Study protocol was not available
Other bias Unclear risk Study was terminated early due to futility
analysis
Power calculation? Low risk Aim was to detect a 16.7% mortality re-
duction with rFVIIa, assuming 30% mor-
tality in placebo patients
Hauser 2010b
Methods Multi-centre, double-blind, placebo-controlled RCT
Participants Adult patients who had sustained penetrating trauma and who had received a minimum
of 4 units of red blood cells (RBCs) but had not yet completed an 8th unit within 12
hours of injury
Group 1 = 46
Group 2 = 40
Randomised but not given the allocated treatment = 6
Total randomised = 92
45Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hauser 2010b (Continued)
Interventions Group 1. 3 doses of iv rFVIIa. 200 µg/kg first dose, after 8 units of RBC transfused; 100
µg/kg 1 hour after dose 1; 100 µg/kg 3 hours after dose 1. Total dose 400 µg/kg.
Group 2. Placebo given at each of the 3 time points.
Outcomes Primary:
1. 1st tier endpoint was superiority in all-cause 30-day mortality in blunt trauma
2. If not met, the 2nd tier primary conditional endpoint of non-inferiority of mortality
and superiority on durable morbidity (pulmonary and/or renal dysfunction at day 30)
was applied
Secondary:
3. Transfused units of RBC, plasma, platelets, cryoprecipitate, fibrinogen concentrate
and all allogeneic blood products at 24 hours and 48 hours after dosing and number of
patients requiring massive RBC transfusion (≥ 10 units of RBC) at 24 hours
4. Number of patients with thromboembolic events, multiple organ failure (MOF),
single organ failure (SOF) and days alive and free from MOF, SOF, intensive care unit,
hospital or ventilator, and/or renal replacement therapy, through day 30
Sources of Support Drug supplied by sponsor: Novo Nordisk
Sponsor responsible for data management, assisted with trial design
Analyses performed by sponsor but also repeated by independent statistician and the
latter is presented in the article
Notes Inaccurate denominators were used although intention-to-treat analysis was supposed
to have been performed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation in random permuted
blocks with allocation of every randomisa-
tion block to a specific centre. Randomisa-
tion was confirmed through an interactive
voice response system set up by the Spon-
sor
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Description of placebo as the same formu-
lation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk FFP differences may have been due to
changes in INR, the results of which would
have been available to clinicians and the
transfusion protocol was based on INR re-
sults.
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Hauser 2010b (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis was performed
Selective reporting (reporting bias) Unclear risk Study protocol was not available
Other bias Unclear risk Study was terminated early due to futility
analysis
Power calculation? Low risk Aim was to detect a 16.7% mortality re-
duction with rFVIIa, assuming 30% mor-
tality in placebo patients
Jeffers 2002
Methods Double-blind RCT
Participants Adults
Cirrhosis and coagulopathy undergoing laparoscopic liver biopsy
Group 1 = 16
Group 2 = 14
Group 3 = 17
Group 4 = 19
Total randomised = 66
Interventions Group 1. 1 dose of 5 µg/kg rFVIIa iv 10 minutes before biopsy.
Group 2. 1 dose of 20 µg/kg rFVIIa iv at same time pre-biopsy.
Group 3. 1 dose of 80 µg/kg rFVIIa iv at same time.
Group 4. 1 dose of 120 µg/kg rFVIIa iv at same time.
Outcomes 1. Time to haemostasis assessed visually
2. Duration of normal PT
3. Serial laboratory parameters after rFVIIa infusion including PTT, fibrinogen, D-
dimer, F1+2 and platelets
Sources of Support One author from Novo Nordisk
Notes Some threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation in blocks of 8 and sequentially assigned to 1 of
4 treatment groups. No details of sequence generation given
Allocation concealment (selection bias) Unclear risk No details given
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Jeffers 2002 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double-blind. Injection volume per kg body weight
was the same regardless of rFVIIa dose administered
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated to be double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 4; 6%
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Unclear risk No placebo group. No transfusion guidelines provided.
Power calculation? Unclear risk Done for outcome of duration of normal PT; target not stated
Johansson 2007
Methods Double-blind, placebo-controlled RCT
Participants Adults
Thermal burn undergoing skin excision and grafting
Group 1 = 9
Group 2 = 9
Total randomised = 18
Interventions Group 1. First dose of 40 µg/kg rFVIIa iv given immediately before start of surgery; 2nd
dose given at 90 minutes later. Total dose 80 µg/kg.
Group 2. Placebo as for Group 1.
Outcomes 1. (Primary) Total number of units of blood components transfused per patient and
percentage full-thickness wound excised during and up to 24 hours after surgery
2. Operating time
3. Number of patients with microvascular bleeding
4. Percentage graft survival on day 7 after surgery
5. Days spent in intensive care unit after surgery
6. Days of hospitalisation
7. 30-day mortality
8. Postoperative complications
9. Serial laboratory parameters after surgery including PT-INR, FVII activity, thrombin-
antithrombin complexes, tissue factor and IL-6
Sources of Support Study supported by an unrestricted educational grant from Novo Nordisk and an em-
ployee from Novo Nordisk assisted in preparation of the manuscript
Notes Some threats to validity noted (see ’Risk of bias’ assessment)
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Johansson 2007 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using permuted blocks that were
derived from random number tables
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blind but no details pro-
vided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated to be double-blind but no details pro-
vided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 0; 0%
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Unclear risk Small study size
Power calculation? High risk No power calculation
Lodge 2005a
Methods Double-blind, placebo-controlled RCT
Participants Adults
Partial hepatectomy for liver carcinoma/metastasis, benign tumours or anatomical/non-
anatomical resection
Group 1 = 63
Group 2 = 59
Group 3 = 63
Randomised but not given an allocated treatment = 19
Total randomised = 204
Interventions Group 1. 20 µg/kg rFVIIa by slow iv, within 5 minutes before the first skin incision;
repeated at 5 hours if operation likely to be longer than 6 hours. Total dose 20 or 40 µg/
kg.
Group 2. 80 µg/kg as for group 1. Total dose 80 or 160 µg/kg.
Group 3. Placebo as for group 1.
Outcomes 1. (Primary) Patients requiring erythrocyte (red cell) transfusion during surgery and the
48-hour period after
2. Amount of erythrocytes (red cells) transfused
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Lodge 2005a (Continued)
3. Change in haematocrit
4. Proportion of patients who received perioperative transfusions of fresh frozen plasma
5. Total surgery time
6. Blood loss during and after surgery
7. Adverse events especially thromboembolic events
Sources of Support Novo Nordisk set up randomisation, provided clinical researcher and statistician
Notes Minimal threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation, blocked by centre, was com-
puter-generated by means of central interac-
tive voice response system
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated to be double-blind. An additionalmea-
sure was that clotting blood tests were not re-
leased from the central lab until the trial end
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 19; 9%. 19 patients lost
to follow-up did not undergo partial hepate-
ctomy and lack of clarity on whether losses
to follow-up were spread equally across each
treatment group
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Low risk -
Power calculation? Low risk Done; target 180 (achieved)
Lodge 2005b
Methods Double-blind, placebo-controlled RCT
Participants Adults
End-stage liver disease with cirrhosis prior to orthotopic liver transplantation
Group 1 = 63
Group 2 = 58
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Lodge 2005b (Continued)
Group 3 = 61
Randomised but not given an allocated treatment = 27
Total randomised = 209
Interventions Group 1. Repeated doses of 60 µg/kg rFVIIa iv starting within 10 minutes of skin
incision and then repeated every 2 hours. Most participants had 3 doses. Total dose
approximately 180 µg/kg.
Group 2. As for group 1 but dose 120 µg/kg. Total dose approximately 360 µg/kg.
Group 3. Placebo.
Outcomes 1. (Primary) Total number of red cells units transfused during the perioperative period
defined as surgery + 24 hours postoperatively
2. Other transfusion requirements (FFP, platelets, crystalloids and colloids) during peri-
operative period
3. Blood loss during perioperative period and changes in haematocrit during periopera-
tive period
4. Use of other haemostatic drugs, including antifibrinolytics
5. Length of intensive care and hospital stay
6. Surgery time
7. Adverse events especially thromboembolic events and bleeding complications
Sources of Support One author from Novo Nordisk
Notes Important threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blind but no details pro-
vided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated to be double-blind but no details pro-
vided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up: 27; 13% (26 withdrawn
before dosing and 1 did not complete prean-
hepatic phase of surgery)
Selective reporting (reporting bias) Unclear risk Study protocol not available
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Lodge 2005b (Continued)
Other bias Unclear risk Equality of allocation within each of the 14
centres not assured
Power calculation? Low risk Done; target 180 (achieved)
Ma 2006
Methods Double-blind, placebo-controlled RCT
Participants Adults
Cardiac valve replacement requiring cardio-pulmonary bypass
Group 1 = 11
Group 2 = 11
Total randomised = 22
Interventions Group 1. 1 dose of 40 µg/kg rFVIIa iv after bypass and reversal of heparin.
Group 2. Placebo at same time.
Outcomes 1. Serial haematological parameters including haemoglobin, haematocrit, platelets, PT,
INR, fibrinogen, ACT
2. Postoperative thoracic drainage
3. Postoperative blood transfusion
4. Period of mechanical ventilation
5. Period of ICU stay
6. Hospitalisation costs
Sources of Support No statement made
Notes Important threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed using random
number tables
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blind but no details pro-
vided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated to be double-blind but no details pro-
vided
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Ma 2006 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 0; 0%
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Unclear risk Small study size. No transfusion guidelines.
Power calculation? High risk No power calculation
Mayer 2005a
Methods Double-blind, placebo-controlled RCT
Participants Adults
Spontaneous intracerebral haemorrhage confirmed by CT scan within 3 hours of onset
Group 1 = 108
Group 2 = 92
Group 3 = 103
Group 4 = 96
Total randomised = 400 (one withdrew consent)
Interventions Group 1. 1 dose of 40 µg/kg of iv FVIIa within 1 hour of scan.
Group 2. 1 dose of 80 µg/kg at same time.
Group 3. 1 dose of 160 µg/kg at same time.
Group 4. Placebo at same time.
Outcomes 1. (Primary) Change in volume of intracerebral haemorrhage as assessed by CT scan
between baseline and 24 hours
2. Survival at 90 days
3. Unfavourable Modified Rankin Scale score (4 to 6) at 90 days
4. Unfavourable Extended Glasgow Outcome Scale score (1 to 4) at 90 days
5. Barthel Index score at 90 days
6. NIH Stroke Scale score at 90 days
7. All serious adverse events, particularly thromboembolic, up to 90 days (all adverse
events collected to discharge from hospital)
Sources of Support Study supported by NovoNordisk. Sponsor responsible for collecting the data. 5 authors
received consultancy fees from Novo Nordisk. 3 authors from Novo Nordisk
Notes Some threats to validity (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation in blocks of 4 in sequentially
numbered, identical appearing containers
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Mayer 2005a (Continued)
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double-blind. Indicated that
placebo identical. CT scans analysed in ran-
dom order, double-read, blind to treatment
allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 16; 4%
Selective reporting (reporting bias) Low risk Registered at www.clinicaltrials.gov
Other bias Unclear risk Half of study patients had complete screen-
ing data, precluding full assessment of bal-
ance of population characteristics. Equality
of distribution of patients between the 73
contributing study centres. Inclusion criteria
changedduring trial to exclude thosewith his-
tory of thrombotic or vaso-occlusive disease -
distribution across final study groups not de-
scribed. In analysis for surviving patients with
missing outcome data, last observation was
carried forward
Power calculation? Unclear risk Done; target not stated
Mayer 2005b
Methods Double-blind, placebo-controlled RCT
Participants Adults
Spontaneous intracerebral haemorrhage confirmed by CT scan within 3 hours of onset
Groups 1, 2, 3, 4, 5, 6 = 6
Group 7 = 12
Total randomised = 48 (1 withdrew consent)
Interventions Group 1. 1 dose of 10 µg/kg of iv rFVIIa within 1 hour of scan.
Group 2. 1 dose of 20 µg/kg at same time.
Group 3. 1 dose of 40 µg/kg at same time.
Group 4. 1 dose of 80 µg/kg at same time.
Group 5. 1 dose of 120 µg/kg at same time.
Group 6. 1 dose of 160 µg/kg at same time.
Group 7. Placebo within 1 hour of scan.
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Mayer 2005b (Continued)
Outcomes 1. (Primary) Frequency of adverse events that were possibly or probably treatment related
by day 15 or discharge if earlier. Serious adverse events were considered to day 90; pre-
defined events included MI, DVT, PE, cerebral artery or vein thrombosis, consumptive
coagulopathy, perihaematoma oedema
2. Change in baseline and 24-hour CT
3. In hospital neurological deterioration between day 0 and day 5
4. Percentage of patients dead, alive with minimal or no disability, or alive and function-
ally independent at day 90
Sources of Support Study supported by Novo Nordisk. Statistician from Novo Nordisk
Notes Some threats to validity (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation schedule was generated and
patients were allocated to the next available
randomisation number within the dose tier.
No details given about sequence generation
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double-blind. CT scans anal-
ysed in random sequence by 2 independent
blinded neuroradiologists
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 1; 2%
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Unclear risk Small safety study with no power calculation.
Equality of distribution of patients between
centres. No comparison of population char-
acteristics between study arms
Power calculation? High risk No power calculation
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Mayer 2006
Methods Double-blind, placebo-controlled RCT
Participants Adults
Spontaneous intracerebral haemorrhage confirmed by CT scan within 3 hours of onset
Group 1 = 8
Group 2 = 8
Group 3 = 8
Group 4 = 8
Group 5 = 8
Randomised but not given an allocated treatment = 1
Total randomised = 41
Interventions Group 1. 1 dose of 5 µg/kg of rFVIIa iv within 1 hour of CT scan.
Group 2. 1 dose of 20 µg/kg at same time.
Group 3. 1 dose of 40 µg/kg at same time.
Group 4. 1 dose of 80 µg/kg at same time.
Group 5. Placebo at same time.
Outcomes 1. (Primary) Frequency of adverse events by day 15 or discharge if earlier. Serious adverse
events were considered to day 90. Predefined events included MI, DVT, PE, cerebral
artery or vein thrombosis, consumptive coagulopathy, perihaematoma oedema
2. Change in CT scan at 1 and 24 hours after baseline
3. In hospital neurological deterioration between day 0 and day 5
4. Percentage of patients dead, alive with minimal or no disability, or alive and function-
ally independent at day 90
Sources of Support Study supported by Novo Nordisk. One author from Novo Nordisk. Agreement to
publish results regardless of outcome
Notes Some threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned in 4 sequential dose tiers
(n = 10 per tier) to receive placebo (n = 2
per tier) or product at 4 different doses (n =
8 per tier). No details given about sequence
generation
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double-blind. Active agent and
placebo were provided as indistinguishable
powders for reconstitution
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Mayer 2006 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated to be double-blind. CT scans anal-
ysed in random sequence by 2 independent
blinded neuroradiologists
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 1; 2%
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Unclear risk Small study size. Equality of distribution of
patients among centres unclear. 2 patients
(5%) were treated beyond 4 hours of onset
Power calculation? High risk No power calculation
Mayer 2008
Methods Double-blind, placebo-controlled RCT
Participants Adults
Spontaneous intracerebral haemorrhage confirmed by CT scan within 3 hours of onset
Group 1 = 265
Group 2 = 293
Group 3 = 263
Randomised but not given an allocated treatment = 20
Total randomised = 841
Interventions Group 1. 1 dose of 20 µg/kg of rFVIIa iv within 1 hour of CT scan.
Group 2. 1 dose of 80 µg/kg at same time.
Group 3. Placebo at same time.
Outcomes 1. (Primary) Severe disability or death by modified Rankin scale score of 5 or 6 at day
90
2. Clinical assessment scores at day 90: Barthel index, ExtendedGlasgowOutcome Scale,
NIH Stroke Scale, EuroQoL scale and Revised Hamilton Rating Scale for Depression
3. Change in volume of intracerebral haemorrhage, intraventricular haemorrhage and
oedema as assessed by CT scan between baseline, 24 and 72 hours
4. All adverse events until discharge and serious adverse events, particularly thromboem-
bolic, up to 90 days
Sources of Support Study supported by Novo Nordisk. Sponsor responsible for trial operations including
data analysis
Notes Some threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
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Mayer 2008 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation according to site
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk CT scans analysed by 2 independent blinded
neuroradiologists
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 22; 3%
Selective reporting (reporting bias) Low risk Registered at www.clinicaltrials.gov
Other bias Low risk External generalisability is a concern as less
than 10% who were assessed for eligibility for
the trial underwent randomisation. In anal-
ysis for surviving patients with missing out-
come data, last observation was carried for-
ward
Power calculation? Low risk Done; target 816 (achieved)
Narayan 2008
Methods Double-blind, placebo-controlled RCT
Dose-escalation trial
Participants Adult
Traumatic brain injury with contusion of total volume of at least 2 mL on CT scan
obtained within 6 hours of injury
Group 1 = 12
Group 2 = 11
Group 3 = 14
Group 4 = 12
Group 5 = 12
Group 6 = 36
Total randomised = 97
Interventions Group 1. 1 dose of 40 µg/kg of rFVIIa iv within 2.5 hours of CT scan.
Group 2. 1 dose of 80 µg/kg at same time.
Group 3. 1 dose of 120 µg/kg at same time.
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Group 4. 1 dose of 160 µg/kg at same time.
Group 5. 1 dose of 200 µg/kg at same time.
Group 6. Placebo at same time.
Outcomes 1. (Primary) Safety: occurrence of AEs, serious AEs, predefined potential thromboem-
bolic AEs (deep venous thrombosis, pulmonary embolus, myocardial infarction, cerebral
infarction, DIC, coagulopathy) and mortality within 15-day trial period
2. Changes in haematoma volume on CT scan at baseline compared with 24 hours and
72 hours after dosing
3. Clinical outcomes at day 15: Glasgow Coma Scale, extended Glasgow Outcome Scale
and Barthel Index
Sources of Support Novo Nordisk supplied study agent and placebo. 2 authors from Novo Nordisk
Notes Some threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated as double-blind but no details pro-
vided
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk 2 independent neuroradiologists assessed
CT scans masked to patient, treatment arm
and study site information
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 0; 0%
Selective reporting (reporting bias) Low risk Registered at www.clinicaltrials.gov
Other bias Unclear risk Inclusion criteria amended after 8% of pa-
tients entered study to improve recruitment
(reducing minimal lesion volume from 5
mL to 2 mL; GCS scores changed from 4-
13 to 4-14; time of CT scan from within 4
to within 6 hours). External generalisabil-
ity is a concern as 4% who were assessed
for eligibility for the trial underwent ran-
domisation. Follow-up data available up to
15 days post-dosing
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Power calculation? High risk No power calculation
Pihusch 2005
Methods Double-blind, placebo-controlled RCT
Participants Adults (all included patients > 16 years old, although inclusion criteria allowed > 12
years)
Bleeding occurring 2 to 120 days (or 180 days later in study) after haematopoietic
stem cell grafts (initially allogeneic, later in study autologous included) for a variety of
haematological and oncological conditions
Group 1 = 20
Group 2 = 26
Group 3 = 31
Group 4 = 23
Total randomised = 100
Interventions Group 1. 7 x 40 µg/kg of iv rFVIIa given every 6 hours; total dose 280 µg/kg.
Group 2. As for group 1, but 7 x 80 µg/kg; total dose 560 µg/kg.
Group 3. As for group 1 but 7 x 160 µg/kg; total dose 1120 µg/kg.
Group 4. Placebo.
Outcomes 1. (Primary) Change in bleeding score (5-point scale 0 to 4) from baseline to 38 hours
after initial dose
2. Changes in bleeding scores over other periods
3. Use of RBC, platelets and FFP over 96-hour trial period
4. Adverse events and serious adverse events over 96-hour trial period
Sources of Support Novo Nordisk support in all phases of the trial. 2 authors from Novo Nordisk
Notes Important threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated, using centre blocks
with equal allocation ratio between treatment
groups
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double-blind. Indicated that
placebo identical.
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated to be double-blind.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 2; 2%
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias High risk Stopped recruiting patients where bleeding
event triggering trial entry was haemorrhagic
cystitis (HC) (“bleeding from urinary blad-
der”) after an interim analysis (p1938 col2)
. However, there was a marked imbalance
in patients with HC across study groups be-
ing much reduced in the 80 µg/kg treatment
group
Power calculation? Low risk Done; target 100 (achieved)
Planinsic 2005
Methods Double-blind, placebo-controlled RCT
Participants Adults
End-stage liver disease prior to orthotopic liver transplantation
Group 1 = 18
Group 2 = 24
Group 3 = 22
Group 4 = 19
Randomised but not given an allocated treatment = 4
Total randomised = 87
Interventions Group 1. 1 dose rFVIIa 20 µg/kg iv within 10 minutes of the first skin incision.
Group 2. 1 dose 40 µg/kg FVIIa, otherwise as for group 1.
Group 3. 1 dose 80 µg/kg FVIIa, otherwise as for group 1.
Group 4. Placebo.
Outcomes 1. (Primary) Total number of red cells units transfused during the perioperative period
defined as surgery + 24 hours postoperatively
2. Other transfusion requirements during the perioperative period (FFP, platelets, crys-
talloids and colloids)
3. Blood loss recorded during the perioperative period
4. Use of other haemostatic drugs, including antifibrinolytics
5. Length of intensive care unit stay
6. Adverse events especially thromboembolic events and bleeding complications
Sources of Support One author from Novo Nordisk
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Notes Some threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk In blocks of 8 equally allocated across 4 treat-
ment groups. No other details
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated to be double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 5; 5%
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Low risk -
Power calculation? Low risk Done; target 80 (achieved)
Pugliese 2007
Methods Double-blind, placebo-controlled RCT
Participants Adults
End-stage liver disease prior to orthotopic liver transplantation
Group 1 = 10
Group 2 = 10
Total randomised = 20
Interventions Group 1. 1 dose of 40 µg/kg rFVIIa iv immediately before anaesthesia induction.
Group 2. Placebo at same time.
Outcomes 1. Change in INR
2. Blood products transfused during surgery
3. Blood loss during surgery
Sources of Support No statement made
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Notes Important threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blind but no details pro-
vided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated to be double-blind but no details pro-
vided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 0; 0%
Selective reporting (reporting bias) Unclear risk Some results reported in abstract but not in
results section
Other bias Unclear risk Not enough information to determine if
groups were balanced. Small study size
Power calculation? High risk No power calculation
Raobaikady 2005
Methods Double-blind, placebo-controlled RCT
Participants Adults
Reconstructive surgery for traumatic fractures of the pelvis or pelvis and acetabulum
Group 1 = 24
Group 2 = 24
Total randomised = 48
Interventions Group 1. 90 µg/kg rFVIIa iv at first skin incision plus a further dose after 2 hours if there
was evidence of significant bleeding. Total dose 90 to 180 µg/kg.
Group 2. Placebo.
Outcomes 1. (Primary)Total volume of perioperative blood loss (surgery +48hours postoperatively)
2. Transfusion requirements
3. Numbers of patients transfused
4. Volume of crystalloids/colloids infused
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5. Surgery time
6. Time to reach normal body temperature and acid-base status
7. Time in ICU
8. Days in hospital
9. Number of times returned to operating theatre
10. Adverse events focusing on thromboembolic events
Sources of Support Study supported by Novo Nordisk. Novo Nordisk assisted in preparation of manuscript.
One author worked as consultant for Novo Nordisk
Notes Some threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated scheme
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blind but no details pro-
vided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated to be double-blind but no details pro-
vided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 0; 0%
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Low risk -
Power calculation? Low risk Done; target 48 (achieved)
Sachs 2007
Methods Double-blind, placebo-controlled RCT
Participants Adults
Spinal fusion surgery reaching dosing trigger of 10% loss of estimated blood volume
with total expected loss of at least 20% estimated blood volume before end of surgery
Group 1 = 12
Group 2 = 12
Group 3 = 12
64Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sachs 2007 (Continued)
Group 4 = 13
Randomised but not given an allocated treatment = 11
Total randomised = 60
Interventions Group 1. 3 x 30 µg/kg rFVIIa iv. First dose at dosing trigger; second dose at 2 hours
after initial dose; third dose at 4 hours after initial dose. Total dose 90 µg/kg.
Group 2. 3 x 60 µg/kg rFVIIa iv at same times. Total dose 180 µg/kg.
Group 3. 3 x 120 µg/kg rFVIIa iv at same times. Total dose 360 µg/kg.
Group 4. Placebo, powder for reconstitution, at same times.
Outcomes 1. (Primary) All serious adverse events to 30 days post-surgery, thrombotic serious adverse
events, changes in laboratory parameters and all adverse events from baseline visit until
discharge
2. (Co-primary) Adjusted volume of blood loss
3. Rate of blood loss
4. Units/volume of allogeneic and autologous RBC, FFP, platelets and cryoprecipitate
transfused
5. Duration of surgery
6. Time to drain removal
Sources of Support Study supported by Novo Nordisk. 2 authors from Novo Nordisk.
Notes Some threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double-blind. Active agent and
placebo were provided as indistinguishable
powders for reconstitution
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated to be double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up; 11; 18% (all 11 did not
reach dosing trigger)
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Unclear risk Unclear if groups were balanced. Power cal-
culation based on assumed increase in throm-
botic events from 2% for placebo to 15%
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Sachs 2007 (Continued)
for rFVIIa leading to an underpowered study.
Marked differences between the unadjusted
and adjusted analyses.
Power calculation? Low risk Done; target 48 (achieved)
Shao 2006
Methods Double-blind, placebo-controlled RCT
Participants Adults
Partial hepatectomy for liver cancer or benign tumours in patients with cirrhosis
Group 1 = 71
Group 2 = 74
Group 3 = 76
Randomised but not given an allocated treatment = 14
Total randomised = 235
Interventions Group 1. First dose of 50 µg/kg rFVIIa iv within 10 minutes before first skin cut with
additional doses given every 2 hours until the end of surgery to a maximum dose of 4
doses.
Group 2. 100 µg/kg iv as for Group 1.
Group 3. Placebo as for Group 1.
Outcomes 1. (Primary) Proportion of patients receiving RBC transfusions during surgery and the
first 48 hours after surgery
2. (Co-primary) Amount of RBCs transfused during surgery and the first 48 hours after
surgery
3. Amounts of FFP and platelets transfused during surgery and the first 48 hours after
surgery
4. Blood loss
5. Proportion of patients receiving systemic haemostatic drugs
6. Changes in coagulation-related parameters including PTT, platelet counts, fibrinogen,
D-dimer, thrombin-anti-thrombin complexes, prothrombin fragments 1+2)
Sources of Support One author from Novo Nordisk
Notes Some threats to validity noted (see ’Risk of bias’ assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk No details given
66Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Shao 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated to be double-blind but no details pro-
vided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated to be double-blind but no details pro-
vided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 14; 6%
Selective reporting (reporting bias) Unclear risk Study protocol not available
Other bias Low risk -
Power calculation? Unclear risk Done; no target stated
ACT = activated clotting time
AE = adverse event
ASA = acetylsalicylic acid
CPB = cardiopulmonary bypass
CT = computerised tomography
DIC = disseminated intravascular coagulation
DVT = deep vein thrombosis
FDP = fibrin degradation products
FFP = fresh frozen plasma
GCS = Glasgow Coma Scale
ICU = intensive care unit
INR = international normalised ratio
iv = intravenous
MI = myocardial infarction
MOF = multiple organ failure (MOF)
NIH = National Institutes of Health
PE = pulmonary embolism
PT = prothrombin time
RBC = red blood cell
RCT = randomised controlled trial
rFVIIa = recombinant factor VIIa
SOF = single organ failure
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ashrani 2006 Not a randomised controlled trial
Bijsterveld 2002 Study of human volunteers
Bijsterveld 2004 Study of human volunteers
Boffard 2009 Secondary report
Bysted 2007 Study of human volunteers
Davis 2004 Not a randomised controlled trial
Diringer 2007 Not a randomised controlled trial
Elgafy 2010 Systematic review or meta-analysis
Ensor 2011 Systematic review or meta-analysis
Fridberg 2005 Study of human volunteers
Gurusamy 2009 Systematic review or meta-analysis
Jilma 2002 Study of human volunteers
Johansson 2010 Systematic review or meta-analysis
Kolban 2005 Not a randomised controlled trial
Larsen 2010 Laboratory-based study
Leduc 2009 Systematic review or meta-analysis
Levi 2010 Systematic review or meta-analysis
Lin 2011b Published version of previous Cochrane review
Logan 2010 Narrative review
Macieji 2004 Not a randomised controlled trial
Nishijima 2009 Systematic review or meta-analysis
Perel 2010 Systematic review or meta-analysis
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(Continued)
Perez 2007 Not a randomised controlled trial
Plaat 2007 Not a randomised controlled trial
Pugh 2007 Not a randomised controlled trial
Strydom 2010 Systematic review or meta-analysis
Thabut 2011 Systematic review or meta-analysis
Van De Velde 2007 Not a randomised controlled trial
Vincent 2009 Study was discontinued prematurely by the Safety Committee based on statistical analysis of the mortality in
cohort 3, which suggested that 28-day mortality was significantly higher in this cohort than in the placebo
group and time to death was significantly shorter
Vink 2004 Study of human volunteers
Woltz 2004 Study of human volunteers
Yank 2009 Not a randomised controlled trial
Yank 2011 Systematic review or meta-analysis
Yuan 2010 Systematic review or meta-analysis
Characteristics of ongoing studies [ordered by study ID]
Arai 2005
Trial name or title Randomised, double-blind, multicentre, placebo-controlled dose-escalation study to evaluate the safety and
preliminary efficacy of activated recombinant factor VII (NN-007) in acute intracerebral haemorrhage
Methods Double-blind, placebo-controlled RCT
Dose-escalation trial
Participants Adults
Spontaneous ICH diagnosed by CT scan within 3 hours of symptom onset
Group 1 = 15
Group 2 = 15
Group 3 = 15
Group 4 = 45
Total randomised = 90
Interventions Group 1. 1 dose of 40 µg/kg of rFVIIa iv within 1 hour of CT scan.
Group 2. 1 dose of 80 µg/kg at same time.
Group 3. 1 dose of 120 µg/kg at same time.
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Arai 2005 (Continued)
Group 4. Placebo at same time.
Outcomes 1. Modified Rankin Scale, Barthel Index scores at 15 days post-dose and 90 days post-dose
2. Change in volume of intracerebral haemorrhage, total haemorrhage volume (intracerebral haemorrhage +
intraventricular haemorrhage) and total lesion volumes (ICH + IVH + oedema) as assessed by CT scan from
baseline to 24, 48 and 72 hours post-dose
3. Change in Glasgow Coma Scale and the National Institute of Health’s Stroke Scale (NIHSS) scores from
baseline to 1 hour, 24 hours, 48 hours, 72 hours, 15 days and 90 days post-dose
4. Mortality at 90 days post-dose
5. Occurrence of thromboembolic serious adverse events
6. Changes in laboratory coagulation parameters from prior to dosing to 1, 24, 48 and 72 hours post-dose
7. Occurrence of adverse events until discharge or 90 days post-dose, whichever came first and serious adverse
events
Starting date January 2006 to April 2007
Contact information Morio Arai MD, PhD, Study Director, Novo Nordisk Pharma Ltd.
Notes Completed. Not yet published.
Flaherty 2008
Trial name or title The spot sign for predicting and treating intracerebral haemorrhage growth
Methods Double-blind, placebo-controlled RCT
Participants Participants with ICH who are determined by CT angiogram to be at high risk for haemorrhage growth (CT
angiogram “spot sign” positive)
Estimated enrolment: 184
Interventions Recombinant FVIIa
Outcomes 1. Life-threatening thromboembolic complications (acute myocardial infarction, acute cerebral ischaemia and
acute pulmonary embolism)
2. Rate of haematoma growth
3. Sensitivity and specificity of the spot sign for predicting haematoma growth
4. Incidence of other thromboembolic complications (deep venous thrombosis, elevations in troponin not
associated with ECG changes)
5. Modified Rankin Scale score at 90 days
6. Positive and negative predictive values of the spot sign
Starting date November 2010 to January 2013
Contact information Janice A. Carrozzella, RN, BA, RT(R)
Notes Recruiting
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Gajewski 2005
Trial name or title A multi-center, randomized, double-blind, parallel groups, placebo-controlled trial on efficacy and safety
of activated recombinant factor VII (rFVIIa/NovoSeven) in the treatment of bleeding in patients following
hematopoietic stem cell transplantation (HSCT)
Methods Double-blind, placebo-controlled RCT
Participants Patients ≥ 12 years
Post HSCT with active bleeding
Group 1 = 4
Group 2 = 4
Group 3 = 3
Total randomised = 11
Interventions Group 1. 2 days of rFVIIa 40 µg/kg every 6 hours (7 doses) plus standard therapy. Total dose 280 µg/kg.
Group 2. 80 µg/kg as for Group 1. Total dose 560 µg/kg.
Group 3. Placebo as for Group 1.
Outcomes 1. (Primary) Effect on bleeding after 38-hour observation period following initial dosing
2. Transfusion requirements for RBCs, platelets, FFP in a 4-day observation period
3. Bleeding evaluation at time points of 24, 48, 72, and 96 hours
4. Adverse events were recorded for the 38-hour observation period plus an additional 58 hours (96 hours of
safety assessments)
5. Changes in safety coagulation parameters
Starting date June 2002 to October 2003
Contact information James L. Gajewski
Notes Trial was prematurely terminated due to excessively slow patient recruitment. Planned for 75 (25 per arm)
Gladstone 2011
Trial name or title “Spot sign” selection of intracerebral hemorrhage to guide hemostatic therapy (SPOTLIGHT)
Methods Double-blind, placebo-controlled RCT
Participants Patients with ICH not due to trauma or other known causes with “spot sign” on CT angiography (sign of
active bleeding) who can be treated within 6 hours of onset
Estimated enrolment: 110
Interventions Recombinant FVIIa
Outcomes Primary outcome: ICH size at 24 hours
Starting date May 2011 to August 2016
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Gladstone 2011 (Continued)
Contact information David J Gladstone, MD
416-480-4866
david.gladstone@sunnybrook.ca
Notes Recruiting
Gris 2006
Trial name or title rFVIIa as salvage therapy in severe post-partum haemorrhage
Methods -
Participants Female patients with post-partum haemorrhage responding to none of the existing medical and surgical
treatments
Interventions Recombinant human activated FVII (rhuFVIIa)
Outcomes Primary outcomes:
Clinical parameters: intensity of haemorrhage before and 1 hour after administration of rhuFVIIa; number
of units and volume of RBC, platelets, FFP; haemodynamics-related parameters
Starting date December 2006 to December 2009
Contact information Geraldine Lissalde-Lavigne MD, PhD
geraldine.lavigne@chu-nimes.fr
+33 4 66 68 32 11
Notes Recruitment status is unknown
Imberti 2005
Trial name or title Efficacy and safety of rFVIIa on rebleeding after surgery for spontaneous supratentorial intracerebral haem-
orrhage: a randomised controlled open label investigator blinded pilot study
Methods -
Participants Patients receiving surgery for spontaneous supratentorial intracerebral haemorrhage
Estimated enrolment: 30
Interventions rFVIIa (Eptacog alfa, Novo Nordisk)
Outcomes Primary outcome:
Evaluate the efficacy of Factor VIIa (Eptacog alfa) in preventing or reducing rebleeding after surgery for
spontaneous supratentorial ICH
Secondary outcomes:
Safety of product administration
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Imberti 2005 (Continued)
Starting date January 2005 to December 2008
Contact information Roberto Imberti M.D., Principal Investigator, IRCCS Policlinico S. Matteo - Pavia - Italy
Roberto Imberti M.D.
Tel: +39 0382 502071
r.imberti@smatteo.pv.it
Notes Completed. Not yet published.
Iorio 2006
Trial name or title Randomised, open, prospective, multicenter pilot study to evaluate the efficacy and safety of activated recom-
binant factor VII in acute intracerebral haemorrhage in patients treated with oral anticoagulants or antiplatelet
agents
Methods -
Participants Acute intracerebral haemorrhage in adult patients on treatment with one of the following:
a) oral anticoagulant
b) aspirin, whatever dosage
Estimated enrolment: 32
Interventions rFVIIa
Outcomes Primary outcomes:
EFFICACY: change in ICH volume from prior to dosing to 24 hours
SAFETY: occurrence of clinical adverse events (thromboembolic events, death)
Secondary outcomes:
Difference between groups on the modified Rankin Scale, the Barthel Index (BI), the Extended Glasgow
Scale (EGCS), and the National Institute of Health’s Stroke Scale (NIHSS) at 1 and 3-month follow-up
Starting date September 2005 to September 2006
Contact information Alfonso Iorio, Principal Investigator, University Of Perugia
Tel: +39 075 578 4306
iorioa@unipg.it
Notes Recruitment status is unknown
Kelleher 2006
Trial name or title A multi-centre, randomised, double-blind, placebo-controlled, dose-escalation trial of safety and efficacy of
activated recombinant factor VII (Rfv11a/NovoSeven) in the treatment of post-operative bleeding in patients
following cardiac surgery requiring cardiopulmonary bypass
Methods -
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Kelleher 2006 (Continued)
Participants Patients post-cardiac surgery
Interventions rFVIIa (NovoSeven®)
Outcomes Outcome measures:
Critical serious adverse events: death, acute myocardial infarction, cerebral infarction
Starting date 2006
Contact information Dr Andrea Kelleher, Royal Brompton and Harefield NHS Trust, London SW3 6NP
A.Kelleher@rbh.nthames.nhs.uk
Notes Completed. Not yet published.
McCall 2005
Trial name or title “Salvage use” of rFVIIa after inadequate haemostatic response to conventional therapy in complex cardiac
surgery - a randomised placebo-controlled trial
Methods -
Participants Adult patients with scheduled cardiac surgery undergoing the following procedures:
- double valve replacements or repair
- major thoracic aortic surgery including hypothermic circulatory arrest or descending aortic reconstruction
- valve repair or replacement in the setting of endocarditis
- complex procedures requiring cardiopulmonary bypass duration anticipated to exceed 180 minutes in
patients aged 70 years
Expected enrolment: 40
Interventions rFVIIa
Outcomes Primary outcome:
Adequate haemostasis to enable chest closure after administration of trial medication without the need for
further intervention to improve coagulation
Secondary outcomes:
Percentage of cases that haemostasis after first administration of coagulation factors alone; assessment of
surgical field after administration of trial medication; time to closure of chest after administration of trial
medication; transfusion requirements in post-bypass period in theatre; transfusion requirements in ICU first
12 hours; mediastinal drainage in ICU first 12 hours; coagulation study results at various sample times;
requirement for chest re-exploration; ventilation duration in ICU; duration of stay in ICU
Starting date June 2005 to June 2008
Contact information Austin Health
Melbourne
Victoria
3084
Contact: Peter McCall FANZCA
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McCall 2005 (Continued)
Tel: +61 3 94965000 ext.: 3800
peter.mccall@austin.org.au
Contact backup: Stephanie J Poustie MPH
Tel: +61 3 94965000 ext.: 3800
stephanie.poustie@austin.org.au
Investigator: Peter McCall FANZCA, Principal Investigator
Notes Recruitment status is unknown.
Molter 2005
Trial name or title Effect of rFVIIa on peri-operative blood loss in patients undergoing major burn excision and grafting: a
randomised, double-blind, placebo-controlled parallel assignment efficacy study
Methods -
Participants Patients undergoing major burn excision and grafting
Estimated enrolment: 52
Interventions rFVIIa
Outcomes Reduce perioperative blood loss and transfusion requirements
Starting date January 2006 to December 2010
Contact information Nancy C Molter RN, PhD
Tel: 210 916 5690
Nancy.Molter@amedd.army.mil
Notes Active, but not recruiting
Ng 2006
Trial name or title Use of rFVIIa in bleeding ECMO patients post cardiac surgery. Randomised prospective study
Methods -
Participants Patients post-cardiac surgery
Interventions rFVIIa
Outcomes a) Amount of postoperative bleeding
b) Use of human blood products
Starting date April 2004
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Ng 2006 (Continued)
Contact information Mr C Ng
PICU, Great Ormond Street Hospital, Great Ormond Street, London, WC1N 3JH, UK
Tel: +44 020 7405 9200
Notes Recruitment status is unknown
CT = computerised tomography
FFP = fresh frozen plasma
HSCT = haematopoietic stem cell transplantation
ICH = intracranial haemorrhage
ICU = intensive care unit
iv = intravenous
IVH = intraventriculare hemorrhage
RBC = red blood cell
RCT = randomised controlled trial
rFVIIa = recombinant factor VIIa
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D A T A A N D A N A L Y S E S
Comparison 1. rFVIIa used prophylactically versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 15 1219 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.55, 1.97]
2 Death - exploring heterogeneity 15 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Studies with ≥ 50 patients
each
7 995 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [0.67, 2.78]
2.2 Studies with < 50 patients
each
8 224 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.03, 1.57]
2.3 Studies with adequate
allocation concealment
3 408 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.51, 2.89]
2.4 Studies with transfusion
protocols
13 1121 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.55, 1.97]
3 Total operative and perioperative
blood loss (mL)
10 707 Mean Difference (IV, Random, 95% CI) -296.97 [-416.32, -
177.61]
4 Total operative and perioperative
blood loss (mL) - exploring
heterogeneity
10 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Studies with ≥ 50 patients
each
4 549 Mean Difference (IV, Random, 95% CI) -261.01 [-550.32,
28.29]
4.2 Studies with < 50 patients
each
6 158 Mean Difference (IV, Random, 95% CI) -304.87 [-439.60, -
170.15]
4.3 Studies with adequate
allocation concealment
3 393 Mean Difference (IV, Random, 95% CI) -604.91 [-1259.77,
49.95]
4.4 Studies with transfusion
protocols
9 685 Mean Difference (IV, Random, 95% CI) -342.30 [-479.01, -
205.60]
5 Red cell transfusion requirements
(mL)
12 843 Mean Difference (IV, Random, 95% CI) -260.78 [-367.30, -
154.27]
6 Red cell transfusion requirements
- exploring heterogeneity
12 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Studies with ≥ 50 patients
each
4 618 Mean Difference (IV, Random, 95% CI) -33.42 [-260.27,
193.43]
6.2 Studies with < 50 patients
each
8 225 Mean Difference (IV, Random, 95% CI) -310.57 [-413.14, -
208.00]
6.3 Studies with adequate
allocation concealment
3 393 Mean Difference (IV, Random, 95% CI) -157.57 [-478.84,
163.70]
6.4 Studies with transfusion
protocols
11 821 Mean Difference (IV, Random, 95% CI) -248.42 [-353.13, -
143.70]
7 Numbers of patients transfused 8 868 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.72, 1.01]
8 Numbers of patients transfused -
exploring heterogeneity
8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Studies with ≥ 50 patients
each
5 764 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.86, 0.97]
8.2 Studies with < 50 patients
each
3 104 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.22, 0.89]
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8.3 Studies with adequate
allocation concealment
3 324 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.45, 1.10]
8.4 Studies with transfusion
protocols
7 792 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.66, 1.01]
9 Total thromboembolic events 13 1159 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.82, 2.25]
10 Total thromboembolic events -
exploring heterogeneity
13 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Studies with ≥ 50
patients each
7 995 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.81, 2.37]
10.2 Studies with < 50
patients each
6 164 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.24, 5.13]
Comparison 2. rFVIIa used therapeutically versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 13 2856 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.06]
2 Death - exploring heterogeneity 13 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Studies with ≥ 50 patients
each
10 2744 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.07]
2.2 Studies with < 50 patients
each
3 112 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.22, 3.03]
2.3 Studies with adequate
concealment allocation
6 1545 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.69, 1.16]
2.4 Studies with transfusion
protocols
5 1146 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.77, 1.30]
2.5 Studies without
transfusion protocols
8 1704 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.71, 1.05]
3 Control of bleeding (number of
patients with reduced bleeding)
4 616 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.88, 1.03]
4 Control of bleeding - exploring
heterogeneity
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Studies with ≥ 50 patients
each
3 571 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.88, 1.03]
5 Red cell transfusion requirements
(mL)
5 911 Mean Difference (IV, Random, 95% CI) -88.60 [-263.88, 86.
68]
6 Red cell transfusion requirements
(mL) - exploring heterogeneity
4 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Studies with ≥ 50 patients
each
4 886 Mean Difference (IV, Random, 95% CI) -131.20 [-360.09,
97.69]
7 Number of patients transfused 3 585 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.88, 1.00]
8 Total thromboembolic events 13 2873 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.89, 1.47]
9 Total thromboembolic events -
exploring heterogeneity
13 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Studies with ≥ 50 patients
each
10 2761 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.91, 1.54]
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9.2 Studies with < 50 patients
each
3 112 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.27, 1.92]
9.3 Studies with adequate
allocation concealment
6 1566 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.70, 1.76]
9.4 Studies with transfusion
protocols
5 1167 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.74, 1.52]
Comparison 3. rFVIIa used prophylactically or therapeutically versus placebo (adverse events)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total thromboembolic events 26 4032 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.94, 1.48]
2 Cardiovascular events, including
myocardial infarction
24 3472 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.85, 2.15]
3 Stroke 23 3289 Risk Ratio (M-H, Random, 95% CI) 1.49 [0.72, 3.07]
4 Total arterial events 25 3849 Risk Ratio (M-H, Random, 95% CI) 1.45 [1.02, 2.05]
5 Total venous events 25 3849 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.67, 1.26]
Analysis 1.1. Comparison 1 rFVIIa used prophylactically versus placebo, Outcome 1 Death.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 1 rFVIIa used prophylactically versus placebo
Outcome: 1 Death
Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Friederich 2003 0/24 0/12 0.0 [ 0.0, 0.0 ]
Raobaikady 2005 0/24 0/24 0.0 [ 0.0, 0.0 ]
Planinsic 2005 4/64 1/19 1.19 [ 0.14, 10.00 ]
Lodge 2005a 4/132 3/68 0.69 [ 0.16, 2.98 ]
Lodge 2005b 3/121 1/62 1.54 [ 0.16, 14.47 ]
Diprose 2005 0/10 1/10 0.33 [ 0.02, 7.32 ]
Ekert 2006 0/40 0/36 0.0 [ 0.0, 0.0 ]
Ma 2006 0/11 0/11 0.0 [ 0.0, 0.0 ]
Shao 2006 3/151 0/81 3.78 [ 0.20, 72.22 ]
0.01 0.1 1 10 100
Favours rFVIIa Favours control
(Continued . . . )
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Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Johansson 2007 0/9 3/9 0.14 [ 0.01, 2.42 ]
Essam 2007 0/15 0/15 0.0 [ 0.0, 0.0 ]
Pugliese 2007 0/10 0/10 0.0 [ 0.0, 0.0 ]
Sachs 2007 1/36 0/13 1.14 [ 0.05, 26.25 ]
Gill 2009 10/104 4/68 1.63 [ 0.53, 5.00 ]
Hanna 2010 0/15 0/15 0.0 [ 0.0, 0.0 ]
Total (95% CI) 766 453 1.04 [ 0.55, 1.97 ]
Total events: 25 (rFVIIa), 13 (Control)
Heterogeneity: Chi2 = 4.21, df = 7 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours rFVIIa Favours control
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Analysis 1.2. Comparison 1 rFVIIa used prophylactically versus placebo, Outcome 2 Death - exploring
heterogeneity.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 1 rFVIIa used prophylactically versus placebo
Outcome: 2 Death - exploring heterogeneity
Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies with ≥ 50 patients each
Planinsic 2005 4/64 1/19 1.19 [ 0.14, 10.00 ]
Lodge 2005a 4/132 3/68 0.69 [ 0.16, 2.98 ]
Lodge 2005b 3/121 1/62 1.54 [ 0.16, 14.47 ]
Shao 2006 3/151 0/81 3.78 [ 0.20, 72.22 ]
Ekert 2006 0/40 0/36 0.0 [ 0.0, 0.0 ]
Sachs 2007 1/36 0/13 1.14 [ 0.05, 26.25 ]
Gill 2009 10/104 4/68 1.63 [ 0.53, 5.00 ]
Subtotal (95% CI) 648 347 1.36 [ 0.67, 2.78 ]
Total events: 25 (rFVIIa), 9 (Control)
Heterogeneity: Chi2 = 1.44, df = 5 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
2 Studies with < 50 patients each
Friederich 2003 0/24 0/12 0.0 [ 0.0, 0.0 ]
Raobaikady 2005 0/24 0/24 0.0 [ 0.0, 0.0 ]
Diprose 2005 0/10 1/10 0.33 [ 0.02, 7.32 ]
Ma 2006 0/11 0/11 0.0 [ 0.0, 0.0 ]
Pugliese 2007 0/10 0/10 0.0 [ 0.0, 0.0 ]
Johansson 2007 0/9 3/9 0.14 [ 0.01, 2.42 ]
Essam 2007 0/15 0/15 0.0 [ 0.0, 0.0 ]
Hanna 2010 0/15 0/15 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 118 106 0.20 [ 0.03, 1.57 ]
Total events: 0 (rFVIIa), 4 (Control)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
3 Studies with adequate allocation concealment
Friederich 2003 0/24 0/12 0.0 [ 0.0, 0.0 ]
Lodge 2005a 4/132 3/68 0.69 [ 0.16, 2.98 ]
0.01 0.1 1 10 100
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Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gill 2009 10/104 4/68 1.63 [ 0.53, 5.00 ]
Subtotal (95% CI) 260 148 1.21 [ 0.51, 2.89 ]
Total events: 14 (rFVIIa), 7 (Control)
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
4 Studies with transfusion protocols
Friederich 2003 0/24 0/12 0.0 [ 0.0, 0.0 ]
Planinsic 2005 4/64 1/19 1.19 [ 0.14, 10.00 ]
Raobaikady 2005 0/24 0/24 0.0 [ 0.0, 0.0 ]
Lodge 2005a 4/132 3/68 0.69 [ 0.16, 2.98 ]
Lodge 2005b 3/121 1/62 1.54 [ 0.16, 14.47 ]
Diprose 2005 0/10 1/10 0.33 [ 0.02, 7.32 ]
Shao 2006 3/151 0/81 3.78 [ 0.20, 72.22 ]
Sachs 2007 1/36 0/13 1.14 [ 0.05, 26.25 ]
Pugliese 2007 0/10 0/10 0.0 [ 0.0, 0.0 ]
Johansson 2007 0/9 3/9 0.14 [ 0.01, 2.42 ]
Essam 2007 0/15 0/15 0.0 [ 0.0, 0.0 ]
Gill 2009 10/104 4/68 1.63 [ 0.53, 5.00 ]
Hanna 2010 0/15 0/15 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 715 406 1.04 [ 0.55, 1.97 ]
Total events: 25 (rFVIIa), 13 (Control)
Heterogeneity: Chi2 = 4.21, df = 7 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
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Analysis 1.3. Comparison 1 rFVIIa used prophylactically versus placebo, Outcome 3 Total operative and
perioperative blood loss (mL).
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 1 rFVIIa used prophylactically versus placebo
Outcome: 3 Total operative and perioperative blood loss (mL)
Study or subgroup rFVIIa Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Friederich 2003 24 1138 (285) 12 2688 (1376) 2.1 % -1550.00 [ -2336.84, -763.16 ]
Lodge 2005a 122 1227 (1154) 63 1422 (1271) 7.0 % -195.00 [ -569.75, 179.75 ]
Lodge 2005b 99 7977 (9739) 44 8552 (10658) 0.1 % -575.00 [ -4262.50, 3112.50 ]
Diprose 2005 (1) 10 438 (344) 10 770 (634) 5.4 % -332.00 [ -779.07, 115.07 ]
Ma 2006 11 246 (42) 11 381 (69) 21.5 % -135.00 [ -182.74, -87.26 ]
Pugliese 2007 10 740 (131) 10 1140 (112) 18.9 % -400.00 [ -506.82, -293.18 ]
Sachs 2007 36 1680 (1285) 13 2270 (2659) 0.6 % -590.00 [ -2095.14, 915.14 ]
Essam 2007 15 435 (94) 15 620 (108) 20.6 % -185.00 [ -257.46, -112.54 ]
Gill 2009 104 1397 (1288) 68 1728 (1738) 4.8 % -331.00 [ -812.58, 150.58 ]
Hanna 2010 15 507 (143) 15 877 (155) 18.9 % -370.00 [ -476.72, -263.28 ]
Total (95% CI) 446 261 100.0 % -296.97 [ -416.32, -177.61 ]
Heterogeneity: Tau2 = 16624.40; Chi2 = 42.63, df = 9 (P<0.00001); I2 =79%
Test for overall effect: Z = 4.88 (P < 0.00001)
Test for subgroup differences: Not applicable
-1000 -500 0 500 1000
Favours rFVIIa Favours control
(1) Diprose 2005 = Additional data obtained from author
83Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.4. Comparison 1 rFVIIa used prophylactically versus placebo, Outcome 4 Total operative and
perioperative blood loss (mL) - exploring heterogeneity.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 1 rFVIIa used prophylactically versus placebo
Outcome: 4 Total operative and perioperative blood loss (mL) - exploring heterogeneity
Study or subgroup rFVIIa Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Studies with ≥ 50 patients each
Lodge 2005a 122 1227 (1154) 63 1422 (1271) 59.6 % -195.00 [ -569.75, 179.75 ]
Lodge 2005b 99 7977 (9739) 44 8552 (10658) 0.6 % -575.00 [ -4262.50, 3112.50 ]
Sachs 2007 36 1680 (1285) 13 2270 (2659) 3.7 % -590.00 [ -2095.14, 915.14 ]
Gill 2009 104 1397 (1288) 68 1728 (1738) 36.1 % -331.00 [ -812.58, 150.58 ]
Subtotal (95% CI) 361 188 100.0 % -261.01 [ -550.32, 28.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 3 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.077)
2 Studies with < 50 patients each
Friederich 2003 24 1138 (285) 12 2688 (1376) 2.6 % -1550.00 [ -2336.84, -763.16 ]
Diprose 2005 (1) 10 438 (344) 10 770 (634) 6.7 % -332.00 [ -779.07, 115.07 ]
Ma 2006 11 246 (42) 11 381 (69) 24.2 % -135.00 [ -182.74, -87.26 ]
Pugliese 2007 10 740 (131) 10 1140 (112) 21.6 % -400.00 [ -506.82, -293.18 ]
Essam 2007 15 435 (94) 15 620 (108) 23.3 % -185.00 [ -257.46, -112.54 ]
Hanna 2010 15 507 (143) 15 877 (155) 21.6 % -370.00 [ -476.72, -263.28 ]
Subtotal (95% CI) 85 73 100.0 % -304.87 [ -439.60, -170.15 ]
Heterogeneity: Tau2 = 18910.82; Chi2 = 42.07, df = 5 (P<0.00001); I2 =88%
Test for overall effect: Z = 4.44 (P < 0.00001)
3 Studies with adequate allocation concealment
Friederich 2003 24 1138 (285) 12 2688 (1376) 26.7 % -1550.00 [ -2336.84, -763.16 ]
Lodge 2005a 122 1227 (1154) 63 1422 (1271) 38.1 % -195.00 [ -569.75, 179.75 ]
Gill 2009 104 1397 (1288) 68 1728 (1738) 35.2 % -331.00 [ -812.58, 150.58 ]
Subtotal (95% CI) 250 143 100.0 % -604.91 [ -1259.77, 49.95 ]
Heterogeneity: Tau2 = 256671.87; Chi2 = 9.43, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 1.81 (P = 0.070)
4 Studies with transfusion protocols
Friederich 2003 24 1138 (285) 12 2688 (1376) 2.7 % -1550.00 [ -2336.84, -763.16 ]
Lodge 2005a 122 1227 (1154) 63 1422 (1271) 9.0 % -195.00 [ -569.75, 179.75 ]
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Study or subgroup rFVIIa Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Lodge 2005b 99 7977 (9739) 44 8552 (10658) 0.1 % -575.00 [ -4262.50, 3112.50 ]
Diprose 2005 (2) 10 438 (344) 10 770 (634) 7.0 % -332.00 [ -779.07, 115.07 ]
Pugliese 2007 10 740 (131) 10 1140 (112) 24.0 % -400.00 [ -506.82, -293.18 ]
Sachs 2007 36 1680 (1285) 13 2270 (2659) 0.8 % -590.00 [ -2095.14, 915.14 ]
Essam 2007 15 435 (94) 15 620 (108) 26.0 % -185.00 [ -257.46, -112.54 ]
Gill 2009 104 1397 (1288) 68 1728 (1738) 6.3 % -331.00 [ -812.58, 150.58 ]
Hanna 2010 15 507 (143) 15 877 (155) 24.0 % -370.00 [ -476.72, -263.28 ]
Subtotal (95% CI) 435 250 100.0 % -342.30 [ -479.01, -205.60 ]
Heterogeneity: Tau2 = 17310.50; Chi2 = 24.61, df = 8 (P = 0.002); I2 =67%
Test for overall effect: Z = 4.91 (P < 0.00001)
-1000 -500 0 500 1000
Favours rFVIIa Favours control
(1) Diprose 2005 = Additional data obtained from author
(2) Diprose 2005 = Additional data obtained from author
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Analysis 1.5. Comparison 1 rFVIIa used prophylactically versus placebo, Outcome 5 Red cell transfusion
requirements (mL).
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 1 rFVIIa used prophylactically versus placebo
Outcome: 5 Red cell transfusion requirements (mL)
Study or subgroup rFVIIa Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Friederich 2003 24 60 (50) 12 450 (120) 21.1 % -390.00 [ -460.78, -319.22 ]
Planinsic 2005 63 3332 (3704) 19 3330 (2250) 0.6 % 2.00 [ -1361.86, 1365.86 ]
Lodge 2005a 122 1200 (948) 63 1024 (1001) 8.2 % 176.00 [ -122.99, 474.99 ]
Lodge 2005b 118 3444 (4341) 61 3840 (4620) 0.6 % -396.00 [ -1795.15, 1003.15 ]
Diprose 2005 10 234 (597) 10 750 (603) 3.5 % -516.00 [ -1041.92, 9.92 ]
Ma 2006 11 1050 (660) 11 1890 (930) 2.3 % -840.00 [ -1513.92, -166.08 ]
Johansson 2007 9 2760 (1170) 9 5820 (3630) 0.2 % -3060.00 [ -5551.70, -568.30 ]
Sachs 2007 36 910 (607) 13 1421 (2495) 0.6 % -511.00 [ -1881.69, 859.69 ]
Essam 2007 15 317 (334) 15 517 (176) 13.3 % -200.00 [ -391.06, -8.94 ]
Pugliese 2007 10 300 (133) 10 570 (111) 18.9 % -270.00 [ -377.37, -162.63 ]
Gill 2009 (1) 104 638 (826) 68 821 (824) 10.1 % -183.00 [ -435.11, 69.11 ]
Hanna 2010 15 375 (106) 15 612 (114) 20.7 % -237.00 [ -315.78, -158.22 ]
Total (95% CI) 537 306 100.0 % -260.78 [ -367.30, -154.27 ]
Heterogeneity: Tau2 = 12666.09; Chi2 = 28.67, df = 11 (P = 0.003); I2 =62%
Test for overall effect: Z = 4.80 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 rFVIIa used prophylactically versus placebo, Outcome 6 Red cell transfusion
requirements - exploring heterogeneity.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 1 rFVIIa used prophylactically versus placebo
Outcome: 6 Red cell transfusion requirements - exploring heterogeneity
Study or subgroup rFVIIa Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Studies with ≥ 50 patients each
Planinsic 2005 63 3332 (3704) 19 3330 (2250) 2.7 % 2.00 [ -1361.86, 1365.86 ]
Lodge 2005a 122 1200 (948) 63 1024 (1001) 41.8 % 176.00 [ -122.99, 474.99 ]
Lodge 2005b 118 3444 (4341) 61 3840 (4620) 2.6 % -396.00 [ -1795.15, 1003.15 ]
Gill 2009 (1) 104 638 (826) 68 821 (824) 52.9 % -183.00 [ -435.11, 69.11 ]
Subtotal (95% CI) 407 211 100.0 % -33.42 [ -260.27, 193.43 ]
Heterogeneity: Tau2 = 8778.72; Chi2 = 3.49, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 0.29 (P = 0.77)
2 Studies with < 50 patients each
Friederich 2003 24 60 (50) 12 450 (120) 27.8 % -390.00 [ -460.78, -319.22 ]
Diprose 2005 10 234 (597) 10 750 (603) 3.4 % -516.00 [ -1041.92, 9.92 ]
Ma 2006 11 1050 (660) 11 1890 (930) 2.2 % -840.00 [ -1513.92, -166.08 ]
Johansson 2007 9 2760 (1170) 9 5820 (3630) 0.2 % -3060.00 [ -5551.70, -568.30 ]
Pugliese 2007 10 300 (133) 10 570 (111) 23.7 % -270.00 [ -377.37, -162.63 ]
Essam 2007 15 317 (334) 15 517 (176) 15.2 % -200.00 [ -391.06, -8.94 ]
Sachs 2007 36 910 (607) 13 1421 (2495) 0.6 % -511.00 [ -1881.69, 859.69 ]
Hanna 2010 15 375 (106) 15 612 (114) 27.0 % -237.00 [ -315.78, -158.22 ]
Subtotal (95% CI) 130 95 100.0 % -310.57 [ -413.14, -208.00 ]
Heterogeneity: Tau2 = 8537.33; Chi2 = 17.74, df = 7 (P = 0.01); I2 =61%
Test for overall effect: Z = 5.93 (P < 0.00001)
3 Studies with adequate allocation concealment
Friederich 2003 24 60 (50) 12 450 (120) 38.8 % -390.00 [ -460.78, -319.22 ]
Lodge 2005a 122 1200 (948) 63 1024 (1001) 29.4 % 176.00 [ -122.99, 474.99 ]
Gill 2009 (2) 104 638 (826) 68 821 (824) 31.8 % -183.00 [ -435.11, 69.11 ]
Subtotal (95% CI) 250 143 100.0 % -157.57 [ -478.84, 163.70 ]
Heterogeneity: Tau2 = 67991.37; Chi2 = 14.80, df = 2 (P = 0.00061); I2 =86%
Test for overall effect: Z = 0.96 (P = 0.34)
4 Studies with transfusion protocols
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Study or subgroup rFVIIa Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Friederich 2003 24 60 (50) 12 450 (120) 22.0 % -390.00 [ -460.78, -319.22 ]
Planinsic 2005 63 3332 (3704) 19 3330 (2250) 0.6 % 2.00 [ -1361.86, 1365.86 ]
Lodge 2005a 122 1200 (948) 63 1024 (1001) 8.2 % 176.00 [ -122.99, 474.99 ]
Lodge 2005b 118 3444 (4341) 61 3840 (4620) 0.5 % -396.00 [ -1795.15, 1003.15 ]
Diprose 2005 10 234 (597) 10 750 (603) 3.4 % -516.00 [ -1041.92, 9.92 ]
Pugliese 2007 10 300 (133) 10 570 (111) 19.5 % -270.00 [ -377.37, -162.63 ]
Sachs 2007 36 910 (607) 13 1421 (2495) 0.6 % -511.00 [ -1881.69, 859.69 ]
Essam 2007 15 317 (334) 15 517 (176) 13.5 % -200.00 [ -391.06, -8.94 ]
Johansson 2007 9 2760 (1170) 9 5820 (3630) 0.2 % -3060.00 [ -5551.70, -568.30 ]
Gill 2009 (3) 104 638 (826) 68 821 (824) 10.1 % -183.00 [ -435.11, 69.11 ]
Hanna 2010 15 375 (106) 15 612 (114) 21.5 % -237.00 [ -315.78, -158.22 ]
Subtotal (95% CI) 526 295 100.0 % -248.42 [ -353.13, -143.70 ]
Heterogeneity: Tau2 = 11668.49; Chi2 = 26.15, df = 10 (P = 0.004); I2 =62%
Test for overall effect: Z = 4.65 (P < 0.00001)
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Analysis 1.7. Comparison 1 rFVIIa used prophylactically versus placebo, Outcome 7 Numbers of patients
transfused.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 1 rFVIIa used prophylactically versus placebo
Outcome: 7 Numbers of patients transfused
Study or subgroup rFVIIa Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Friederich 2003 3/24 7/12 1.9 % 0.21 [ 0.07, 0.68 ]
Raobaikady 2005 11/24 16/24 7.5 % 0.69 [ 0.41, 1.16 ]
Lodge 2005a 41/122 23/63 10.4 % 0.92 [ 0.61, 1.39 ]
Lodge 2005b 108/118 61/61 28.3 % 0.92 [ 0.87, 0.98 ]
Diprose 2005 3/10 8/10 2.5 % 0.38 [ 0.14, 1.02 ]
Shao 2006 63/145 29/76 13.0 % 1.14 [ 0.81, 1.60 ]
Ekert 2006 30/40 29/36 18.1 % 0.93 [ 0.73, 1.18 ]
Gill 2009 24/35 61/68 18.2 % 0.76 [ 0.60, 0.97 ]
Total (95% CI) 518 350 100.0 % 0.85 [ 0.72, 1.01 ]
Total events: 283 (rFVIIa), 234 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 16.12, df = 7 (P = 0.02); I2 =57%
Test for overall effect: Z = 1.89 (P = 0.058)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 rFVIIa used prophylactically versus placebo, Outcome 8 Numbers of patients
transfused - exploring heterogeneity.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 1 rFVIIa used prophylactically versus placebo
Outcome: 8 Numbers of patients transfused - exploring heterogeneity
Study or subgroup rFVIIa Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Studies with ≥ 50 patients each
Lodge 2005a 41/122 23/63 2.2 % 0.92 [ 0.61, 1.39 ]
Lodge 2005b 108/118 61/61 81.6 % 0.92 [ 0.87, 0.98 ]
Shao 2006 63/145 29/76 3.2 % 1.14 [ 0.81, 1.60 ]
Ekert 2006 30/40 29/36 6.4 % 0.93 [ 0.73, 1.18 ]
Gill 2009 24/35 61/68 6.5 % 0.76 [ 0.60, 0.97 ]
Subtotal (95% CI) 460 304 100.0 % 0.92 [ 0.86, 0.97 ]
Total events: 266 (rFVIIa), 203 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.09, df = 4 (P = 0.39); I2 =2%
Test for overall effect: Z = 2.82 (P = 0.0048)
2 Studies with < 50 patients each
Friederich 2003 3/24 7/12 23.3 % 0.21 [ 0.07, 0.68 ]
Raobaikady 2005 11/24 16/24 48.6 % 0.69 [ 0.41, 1.16 ]
Diprose 2005 3/10 8/10 28.1 % 0.38 [ 0.14, 1.02 ]
Subtotal (95% CI) 58 46 100.0 % 0.44 [ 0.22, 0.89 ]
Total events: 17 (rFVIIa), 31 (Control)
Heterogeneity: Tau2 = 0.19; Chi2 = 3.93, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 2.30 (P = 0.021)
3 Studies with adequate allocation concealment
Friederich 2003 3/24 7/12 11.6 % 0.21 [ 0.07, 0.68 ]
Lodge 2005a 41/122 23/63 38.7 % 0.92 [ 0.61, 1.39 ]
Gill 2009 24/35 61/68 49.6 % 0.76 [ 0.60, 0.97 ]
Subtotal (95% CI) 181 143 100.0 % 0.71 [ 0.45, 1.10 ]
Total events: 68 (rFVIIa), 91 (Control)
Heterogeneity: Tau2 = 0.09; Chi2 = 5.41, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 1.52 (P = 0.13)
4 Studies with transfusion protocols
Friederich 2003 3/24 7/12 3.1 % 0.21 [ 0.07, 0.68 ]
Raobaikady 2005 11/24 16/24 10.9 % 0.69 [ 0.41, 1.16 ]
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Study or subgroup rFVIIa Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lodge 2005a 41/122 23/63 14.3 % 0.92 [ 0.61, 1.39 ]
Lodge 2005b 108/118 61/61 29.0 % 0.92 [ 0.87, 0.98 ]
Diprose 2005 3/10 8/10 4.0 % 0.38 [ 0.14, 1.02 ]
Shao 2006 63/145 29/76 17.0 % 1.14 [ 0.81, 1.60 ]
Gill 2009 24/35 61/68 21.7 % 0.76 [ 0.60, 0.97 ]
Subtotal (95% CI) 478 314 100.0 % 0.82 [ 0.66, 1.01 ]
Total events: 253 (rFVIIa), 205 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 16.84, df = 6 (P = 0.01); I2 =64%
Test for overall effect: Z = 1.82 (P = 0.068)
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Analysis 1.9. Comparison 1 rFVIIa used prophylactically versus placebo, Outcome 9 Total thromboembolic
events.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 1 rFVIIa used prophylactically versus placebo
Outcome: 9 Total thromboembolic events
Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Friederich 2003 1/24 0/12 1.56 [ 0.07, 35.67 ]
Planinsic 2005 8/64 3/19 0.79 [ 0.23, 2.69 ]
Raobaikady 2005 0/24 0/24 0.0 [ 0.0, 0.0 ]
Lodge 2005a 6/132 3/68 1.03 [ 0.27, 3.99 ]
Lodge 2005b 19/121 6/62 1.62 [ 0.68, 3.85 ]
Diprose 2005 2/10 2/10 1.00 [ 0.17, 5.77 ]
Shao 2006 3/151 1/81 1.61 [ 0.17, 15.22 ]
Ekert 2006 0/40 0/36 0.0 [ 0.0, 0.0 ]
Ma 2006 0/11 0/11 0.0 [ 0.0, 0.0 ]
Pugliese 2007 0/10 0/10 0.0 [ 0.0, 0.0 ]
Johansson 2007 0/9 0/9 0.0 [ 0.0, 0.0 ]
Sachs 2007 8/36 2/13 1.44 [ 0.35, 5.94 ]
Gill 2009 7/104 1/68 4.58 [ 0.58, 36.38 ]
Total (95% CI) 736 423 1.35 [ 0.82, 2.25 ]
Total events: 54 (rFVIIa), 18 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.60, df = 7 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 rFVIIa used prophylactically versus placebo, Outcome 10 Total
thromboembolic events - exploring heterogeneity.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 1 rFVIIa used prophylactically versus placebo
Outcome: 10 Total thromboembolic events - exploring heterogeneity
Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Studies with ≥ 50 patients each
Planinsic 2005 8/64 3/19 0.79 [ 0.23, 2.69 ]
Lodge 2005a 6/132 3/68 1.03 [ 0.27, 3.99 ]
Lodge 2005b 19/121 6/62 1.62 [ 0.68, 3.85 ]
Ekert 2006 0/40 0/36 0.0 [ 0.0, 0.0 ]
Shao 2006 3/151 1/81 1.61 [ 0.17, 15.22 ]
Sachs 2007 8/36 2/13 1.44 [ 0.35, 5.94 ]
Gill 2009 7/104 1/68 4.58 [ 0.58, 36.38 ]
Subtotal (95% CI) 648 347 1.39 [ 0.81, 2.37 ]
Total events: 51 (rFVIIa), 16 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.47, df = 5 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
2 Studies with < 50 patients each
Friederich 2003 1/24 0/12 1.56 [ 0.07, 35.67 ]
Raobaikady 2005 0/24 0/24 0.0 [ 0.0, 0.0 ]
Diprose 2005 2/10 2/10 1.00 [ 0.17, 5.77 ]
Ma 2006 0/11 0/11 0.0 [ 0.0, 0.0 ]
Pugliese 2007 0/10 0/10 0.0 [ 0.0, 0.0 ]
Johansson 2007 0/9 0/9 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 88 76 1.11 [ 0.24, 5.13 ]
Total events: 3 (rFVIIa), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
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Analysis 2.1. Comparison 2 rFVIIa used therapeutically versus placebo, Outcome 1 Death.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 2 rFVIIa used therapeutically versus placebo
Outcome: 1 Death
Study or subgroup Favours rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bosch 2004 16/116 11/120 1.50 [ 0.73, 3.10 ]
Boffard 2005a 17/69 22/74 0.83 [ 0.48, 1.42 ]
Boffard 2005b 17/70 18/64 0.86 [ 0.49, 1.53 ]
Chuansumrit 2005 0/16 0/9 0.0 [ 0.0, 0.0 ]
Mayer 2005a 56/303 28/96 0.63 [ 0.43, 0.94 ]
Mayer 2005b 3/36 2/11 0.46 [ 0.09, 2.40 ]
Pihusch 2005 24/77 7/23 1.02 [ 0.51, 2.07 ]
Mayer 2006 7/32 1/8 1.75 [ 0.25, 12.26 ]
Bosch 2008 39/170 25/86 0.79 [ 0.51, 1.21 ]
Mayer 2008 112/557 51/262 1.03 [ 0.77, 1.39 ]
Narayan 2008 7/61 4/36 1.03 [ 0.32, 3.29 ]
Hauser 2010a 26/224 28/250 1.04 [ 0.63, 1.71 ]
Hauser 2010b 8/46 5/40 1.39 [ 0.49, 3.91 ]
Total (95% CI) 1777 1079 0.91 [ 0.78, 1.06 ]
Total events: 332 (Favours rFVIIa), 202 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.62, df = 11 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 rFVIIa used therapeutically versus placebo, Outcome 2 Death - exploring
heterogeneity.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 2 rFVIIa used therapeutically versus placebo
Outcome: 2 Death - exploring heterogeneity
Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Studies with ≥ 50 patients each
Bosch 2004 16/116 11/120 1.50 [ 0.73, 3.10 ]
Boffard 2005a 17/69 22/74 0.83 [ 0.48, 1.42 ]
Boffard 2005b 17/70 18/64 0.86 [ 0.49, 1.53 ]
Mayer 2005a 56/303 28/96 0.63 [ 0.43, 0.94 ]
Pihusch 2005 24/77 7/23 1.02 [ 0.51, 2.07 ]
Bosch 2008 39/170 25/86 0.79 [ 0.51, 1.21 ]
Mayer 2008 112/557 51/262 1.03 [ 0.77, 1.39 ]
Narayan 2008 7/61 4/36 1.03 [ 0.32, 3.29 ]
Hauser 2010a 26/224 28/250 1.04 [ 0.63, 1.71 ]
Hauser 2010b 8/46 5/40 1.39 [ 0.49, 3.91 ]
Subtotal (95% CI) 1693 1051 0.91 [ 0.78, 1.07 ]
Total events: 322 (rFVIIa), 199 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.52, df = 9 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
2 Studies with < 50 patients each
Chuansumrit 2005 0/16 0/9 0.0 [ 0.0, 0.0 ]
Mayer 2005b 3/36 2/11 0.46 [ 0.09, 2.40 ]
Mayer 2006 7/32 1/8 1.75 [ 0.25, 12.26 ]
Subtotal (95% CI) 84 28 0.81 [ 0.22, 3.03 ]
Total events: 10 (rFVIIa), 3 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 1.09, df = 1 (P = 0.30); I2 =8%
Test for overall effect: Z = 0.31 (P = 0.76)
3 Studies with adequate concealment allocation
Bosch 2004 16/116 11/120 1.50 [ 0.73, 3.10 ]
Mayer 2005a 56/303 28/96 0.63 [ 0.43, 0.94 ]
Pihusch 2005 24/77 7/23 1.02 [ 0.51, 2.07 ]
0.1 0.2 0.5 1 2 5 10
Favours rFVIIa Favours control
(Continued . . . )
95Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bosch 2008 39/170 25/86 0.79 [ 0.51, 1.21 ]
Hauser 2010a 26/221 28/247 1.04 [ 0.63, 1.71 ]
Hauser 2010b 8/46 5/40 1.39 [ 0.49, 3.91 ]
Subtotal (95% CI) 933 612 0.90 [ 0.69, 1.16 ]
Total events: 169 (rFVIIa), 104 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.47, df = 5 (P = 0.26); I2 =23%
Test for overall effect: Z = 0.83 (P = 0.41)
4 Studies with transfusion protocols
Bosch 2004 16/116 11/120 1.50 [ 0.73, 3.10 ]
Pihusch 2005 24/77 7/23 1.02 [ 0.51, 2.07 ]
Bosch 2008 39/170 25/86 0.79 [ 0.51, 1.21 ]
Hauser 2010a 26/221 28/247 1.04 [ 0.63, 1.71 ]
Hauser 2010b 8/46 5/40 1.39 [ 0.49, 3.91 ]
Subtotal (95% CI) 630 516 1.00 [ 0.77, 1.30 ]
Total events: 113 (rFVIIa), 76 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.83, df = 4 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
5 Studies without transfusion protocols
Boffard 2005a 17/69 22/74 0.83 [ 0.48, 1.42 ]
Boffard 2005b 17/70 18/64 0.86 [ 0.49, 1.53 ]
Chuansumrit 2005 0/16 0/9 0.0 [ 0.0, 0.0 ]
Mayer 2005a 56/303 28/96 0.63 [ 0.43, 0.94 ]
Mayer 2005b 3/36 2/11 0.46 [ 0.09, 2.40 ]
Mayer 2006 7/32 1/8 1.75 [ 0.25, 12.26 ]
Mayer 2008 112/557 51/262 1.03 [ 0.77, 1.39 ]
Narayan 2008 7/61 4/36 1.03 [ 0.32, 3.29 ]
Subtotal (95% CI) 1144 560 0.86 [ 0.71, 1.05 ]
Total events: 219 (rFVIIa), 126 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.02, df = 6 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
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Analysis 2.3. Comparison 2 rFVIIa used therapeutically versus placebo, Outcome 3 Control of bleeding
(number of patients with reduced bleeding).
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 2 rFVIIa used therapeutically versus placebo
Outcome: 3 Control of bleeding (number of patients with reduced bleeding)
Study or subgroup Control rFVIIa Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bosch 2004 100/119 102/118 58.3 % 0.97 [ 0.87, 1.08 ]
Chuansumrit 2005 4/9 12/16 1.1 % 0.59 [ 0.27, 1.30 ]
Pihusch 2005 13/22 44/76 4.2 % 1.02 [ 0.69, 1.52 ]
Bosch 2008 66/86 142/170 36.4 % 0.92 [ 0.80, 1.05 ]
Total (95% CI) 236 380 100.0 % 0.95 [ 0.88, 1.03 ]
Total events: 183 (Control), 300 (rFVIIa)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.00, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 rFVIIa used therapeutically versus placebo, Outcome 4 Control of bleeding -
exploring heterogeneity.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 2 rFVIIa used therapeutically versus placebo
Outcome: 4 Control of bleeding - exploring heterogeneity
Study or subgroup Control rFVIIa Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Studies with ≥ 50 patients each
Bosch 2004 100/119 102/118 59.1 % 0.97 [ 0.87, 1.08 ]
Pihusch 2005 13/22 34/56 4.0 % 0.97 [ 0.65, 1.46 ]
Bosch 2008 66/86 142/170 36.9 % 0.92 [ 0.80, 1.05 ]
Subtotal (95% CI) 227 344 100.0 % 0.95 [ 0.88, 1.03 ]
Total events: 179 (Control), 278 (rFVIIa)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.44, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
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Analysis 2.5. Comparison 2 rFVIIa used therapeutically versus placebo, Outcome 5 Red cell transfusion
requirements (mL).
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 2 rFVIIa used therapeutically versus placebo
Outcome: 5 Red cell transfusion requirements (mL)
Study or subgroup rFVIIa Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bosch 2004 121 450 (1110) 121 390 (570) 41.1 % 60.00 [ -162.33, 282.33 ]
Chuansumrit 2005 (1) 16 131 (812) 9 103 (102) 16.3 % 28.00 [ -375.41, 431.41 ]
Bosch 2008 76 764 (719) 75 990 (930) 32.1 % -226.00 [ -491.39, 39.39 ]
Hauser 2010a 191 2340 (3180) 228 2730 (3390) 7.3 % -390.00 [ -1020.09, 240.09 ]
Hauser 2010b 39 1500 (2220) 35 2040 (2070) 3.1 % -540.00 [ -1517.62, 437.62 ]
Total (95% CI) 443 468 100.0 % -88.60 [ -263.88, 86.68 ]
Heterogeneity: Tau2 = 6573.65; Chi2 = 4.74, df = 4 (P = 0.32); I2 =16%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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(1) Data provided per kg and converted to mL according to average weights for the mean ages indicated
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Analysis 2.6. Comparison 2 rFVIIa used therapeutically versus placebo, Outcome 6 Red cell transfusion
requirements (mL) - exploring heterogeneity.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 2 rFVIIa used therapeutically versus placebo
Outcome: 6 Red cell transfusion requirements (mL) - exploring heterogeneity
Study or subgroup rFVIIa Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Studies with ≥ 50 patients each
Bosch 2004 121 450 (1110) 121 390 (570) 45.3 % 60.00 [ -162.33, 282.33 ]
Bosch 2008 76 764 (719) 75 990 (930) 38.3 % -226.00 [ -491.39, 39.39 ]
Hauser 2010b 39 1500 (2220) 35 2040 (2070) 5.1 % -540.00 [ -1517.62, 437.62 ]
Hauser 2010a 191 2340 (3180) 228 2730 (3390) 11.3 % -390.00 [ -1020.09, 240.09 ]
Subtotal (95% CI) 427 459 100.0 % -131.20 [ -360.09, 97.69 ]
Heterogeneity: Tau2 = 17265.85; Chi2 = 4.44, df = 3 (P = 0.22); I2 =32%
Test for overall effect: Z = 1.12 (P = 0.26)
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Analysis 2.7. Comparison 2 rFVIIa used therapeutically versus placebo, Outcome 7 Number of patients
transfused.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 2 rFVIIa used therapeutically versus placebo
Outcome: 7 Number of patients transfused
Study or subgroup rFVIIa Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Chuansumrit 2005 5/16 3/9 0.3 % 0.94 [ 0.29, 3.04 ]
Hauser 2010a 191/224 228/250 86.4 % 0.93 [ 0.87, 1.00 ]
Hauser 2010b 39/46 35/40 13.4 % 0.97 [ 0.82, 1.15 ]
Total (95% CI) 286 299 100.0 % 0.94 [ 0.88, 1.00 ]
Total events: 235 (rFVIIa), 266 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 rFVIIa used therapeutically versus placebo, Outcome 8 Total thromboembolic
events.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 2 rFVIIa used therapeutically versus placebo
Outcome: 8 Total thromboembolic events
Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bosch 2004 7/121 7/121 1.00 [ 0.36, 2.76 ]
Boffard 2005a 2/69 3/74 0.71 [ 0.12, 4.15 ]
Boffard 2005b 4/70 3/64 1.22 [ 0.28, 5.24 ]
Chuansumrit 2005 0/16 0/9 0.0 [ 0.0, 0.0 ]
Mayer 2005a 21/303 2/96 3.33 [ 0.79, 13.93 ]
Mayer 2005b 5/36 1/11 1.53 [ 0.20, 11.73 ]
Pihusch 2005 8/77 0/23 5.23 [ 0.31, 87.34 ]
Mayer 2006 7/32 3/8 0.58 [ 0.19, 1.77 ]
Bosch 2008 9/176 7/89 0.65 [ 0.25, 1.69 ]
Mayer 2008 55/558 21/263 1.23 [ 0.76, 2.00 ]
Narayan 2008 13/61 5/36 1.53 [ 0.60, 3.95 ]
Hauser 2010a 36/224 33/250 1.22 [ 0.79, 1.88 ]
Hauser 2010b 2/46 4/40 0.43 [ 0.08, 2.25 ]
Total (95% CI) 1789 1084 1.14 [ 0.89, 1.47 ]
Total events: 169 (rFVIIa), 89 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.44, df = 11 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 rFVIIa used therapeutically versus placebo, Outcome 9 Total thromboembolic
events - exploring heterogeneity.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 2 rFVIIa used therapeutically versus placebo
Outcome: 9 Total thromboembolic events - exploring heterogeneity
Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Studies with ≥ 50 patients each
Bosch 2004 7/121 7/121 1.00 [ 0.36, 2.76 ]
Boffard 2005a 2/69 3/74 0.71 [ 0.12, 4.15 ]
Boffard 2005b 4/70 3/64 1.22 [ 0.28, 5.24 ]
Mayer 2008 55/558 21/263 1.23 [ 0.76, 2.00 ]
Mayer 2005a 21/303 2/96 3.33 [ 0.79, 13.93 ]
Pihusch 2005 8/77 0/23 5.23 [ 0.31, 87.34 ]
Bosch 2008 9/176 7/89 0.65 [ 0.25, 1.69 ]
Hauser 2010a 36/224 33/250 1.22 [ 0.79, 1.88 ]
Hauser 2010b 2/46 4/40 0.43 [ 0.08, 2.25 ]
Narayan 2008 13/61 5/36 1.53 [ 0.60, 3.95 ]
Subtotal (95% CI) 1705 1056 1.18 [ 0.91, 1.54 ]
Total events: 157 (rFVIIa), 85 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.83, df = 9 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.21)
2 Studies with < 50 patients each
Chuansumrit 2005 0/16 0/9 0.0 [ 0.0, 0.0 ]
Mayer 2005b 5/36 1/11 1.53 [ 0.20, 11.73 ]
Mayer 2006 7/32 3/8 0.58 [ 0.19, 1.77 ]
Subtotal (95% CI) 84 28 0.73 [ 0.27, 1.92 ]
Total events: 12 (rFVIIa), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
3 Studies with adequate allocation concealment
Bosch 2004 7/121 7/121 1.00 [ 0.36, 2.76 ]
Mayer 2005a 21/303 2/96 3.33 [ 0.79, 13.93 ]
Pihusch 2005 8/77 0/23 5.23 [ 0.31, 87.34 ]
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Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bosch 2008 9/176 7/89 0.65 [ 0.25, 1.69 ]
Hauser 2010a 36/224 33/250 1.22 [ 0.79, 1.88 ]
Hauser 2010b 2/46 4/40 0.43 [ 0.08, 2.25 ]
Subtotal (95% CI) 947 619 1.11 [ 0.70, 1.76 ]
Total events: 83 (rFVIIa), 53 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 6.19, df = 5 (P = 0.29); I2 =19%
Test for overall effect: Z = 0.46 (P = 0.64)
4 Studies with transfusion protocols
Bosch 2004 7/121 7/121 1.00 [ 0.36, 2.76 ]
Pihusch 2005 8/77 0/23 5.23 [ 0.31, 87.34 ]
Bosch 2008 9/176 7/89 0.65 [ 0.25, 1.69 ]
Hauser 2010a 36/224 33/250 1.22 [ 0.79, 1.88 ]
Hauser 2010b 2/46 4/40 0.43 [ 0.08, 2.25 ]
Subtotal (95% CI) 644 523 1.06 [ 0.74, 1.52 ]
Total events: 62 (rFVIIa), 51 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.78, df = 4 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
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Analysis 3.1. Comparison 3 rFVIIa used prophylactically or therapeutically versus placebo (adverse events),
Outcome 1 Total thromboembolic events.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 3 rFVIIa used prophylactically or therapeutically versus placebo (adverse events)
Outcome: 1 Total thromboembolic events
Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Friederich 2003 1/24 0/12 1.56 [ 0.07, 35.67 ]
Planinsic 2005 8/64 3/19 0.79 [ 0.23, 2.69 ]
Bosch 2004 7/121 7/121 1.00 [ 0.36, 2.76 ]
Boffard 2005a 2/69 3/74 0.71 [ 0.12, 4.15 ]
Boffard 2005b 4/70 3/64 1.22 [ 0.28, 5.24 ]
Chuansumrit 2005 0/16 0/9 0.0 [ 0.0, 0.0 ]
Diprose 2005 2/10 2/10 1.00 [ 0.17, 5.77 ]
Lodge 2005a 6/132 3/68 1.03 [ 0.27, 3.99 ]
Lodge 2005b 19/121 6/62 1.62 [ 0.68, 3.85 ]
Mayer 2005a 21/303 2/96 3.33 [ 0.79, 13.93 ]
Mayer 2005b 5/36 1/11 1.53 [ 0.20, 11.73 ]
Pihusch 2005 8/77 0/23 5.23 [ 0.31, 87.34 ]
Raobaikady 2005 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ekert 2006 0/40 0/36 0.0 [ 0.0, 0.0 ]
Ma 2006 0/11 0/11 0.0 [ 0.0, 0.0 ]
Mayer 2006 7/32 3/8 0.58 [ 0.19, 1.77 ]
Shao 2006 3/151 1/81 1.61 [ 0.17, 15.22 ]
Johansson 2007 0/9 0/9 0.0 [ 0.0, 0.0 ]
Pugliese 2007 0/10 0/10 0.0 [ 0.0, 0.0 ]
Sachs 2007 8/36 2/13 1.44 [ 0.35, 5.94 ]
Bosch 2008 9/176 7/89 0.65 [ 0.25, 1.69 ]
Mayer 2008 55/558 21/263 1.23 [ 0.76, 2.00 ]
Narayan 2008 13/61 5/36 1.53 [ 0.60, 3.95 ]
Gill 2009 7/104 1/68 4.58 [ 0.58, 36.38 ]
Hauser 2010a 36/224 33/250 1.22 [ 0.79, 1.88 ]
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Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hauser 2010b 2/46 4/40 0.43 [ 0.08, 2.25 ]
Total (95% CI) 2525 1507 1.18 [ 0.94, 1.48 ]
Total events: 223 (rFVIIa), 107 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.40, df = 19 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 rFVIIa used prophylactically or therapeutically versus placebo (adverse events),
Outcome 2 Cardiovascular events, including myocardial infarction.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 3 rFVIIa used prophylactically or therapeutically versus placebo (adverse events)
Outcome: 2 Cardiovascular events, including myocardial infarction
Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Planinsic 2005 1/64 0/19 0.92 [ 0.04, 21.78 ]
Friederich 2003 1/24 0/12 1.56 [ 0.07, 35.67 ]
Bosch 2004 0/121 0/121 0.0 [ 0.0, 0.0 ]
Boffard 2005a 0/69 0/74 0.0 [ 0.0, 0.0 ]
Boffard 2005b 0/70 0/64 0.0 [ 0.0, 0.0 ]
Chuansumrit 2005 0/16 0/9 0.0 [ 0.0, 0.0 ]
Diprose 2005 1/10 1/10 1.00 [ 0.07, 13.87 ]
Lodge 2005a 2/132 0/68 2.59 [ 0.13, 53.28 ]
Lodge 2005b 10/121 2/62 2.56 [ 0.58, 11.33 ]
Mayer 2005a 7/303 0/96 4.79 [ 0.28, 83.04 ]
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Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mayer 2005b 4/36 0/11 2.92 [ 0.17, 50.37 ]
Pihusch 2005 2/77 0/23 1.54 [ 0.08, 30.95 ]
Raobaikady 2005 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ekert 2006 0/40 0/36 0.0 [ 0.0, 0.0 ]
Ma 2006 0/11 0/11 0.0 [ 0.0, 0.0 ]
Mayer 2006 4/32 2/8 0.50 [ 0.11, 2.26 ]
Shao 2006 1/151 0/81 1.62 [ 0.07, 39.28 ]
Johansson 2007 0/9 0/9 0.0 [ 0.0, 0.0 ]
Pugliese 2007 0/10 0/10 0.0 [ 0.0, 0.0 ]
Sachs 2007 7/36 2/13 1.26 [ 0.30, 5.32 ]
Bosch 2008 3/176 0/89 3.56 [ 0.19, 68.16 ]
Mayer 2008 25/558 8/263 1.47 [ 0.67, 3.22 ]
Narayan 2008 5/61 3/36 0.98 [ 0.25, 3.87 ]
Gill 2009 0/104 1/68 0.22 [ 0.01, 5.30 ]
Total (95% CI) 2255 1217 1.35 [ 0.85, 2.15 ]
Total events: 73 (rFVIIa), 19 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.78, df = 14 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours rFVIIa Favours control
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Analysis 3.3. Comparison 3 rFVIIa used prophylactically or therapeutically versus placebo (adverse events),
Outcome 3 Stroke.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 3 rFVIIa used prophylactically or therapeutically versus placebo (adverse events)
Outcome: 3 Stroke
Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Planinsic 2005 0/64 0/19 0.0 [ 0.0, 0.0 ]
Friederich 2003 0/24 0/12 0.0 [ 0.0, 0.0 ]
Bosch 2004 2/121 0/121 5.00 [ 0.24, 103.07 ]
Boffard 2005a 0/69 0/74 0.0 [ 0.0, 0.0 ]
Boffard 2005b 1/70 1/64 0.91 [ 0.06, 14.32 ]
Chuansumrit 2005 0/16 0/9 0.0 [ 0.0, 0.0 ]
Diprose 2005 1/10 1/10 1.00 [ 0.07, 13.87 ]
Lodge 2005a 0/132 0/68 0.0 [ 0.0, 0.0 ]
Mayer 2005a 9/303 0/96 6.06 [ 0.36, 103.21 ]
Mayer 2005b 0/36 0/11 0.0 [ 0.0, 0.0 ]
Pihusch 2005 2/77 0/23 1.54 [ 0.08, 30.95 ]
Raobaikady 2005 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ekert 2006 0/40 0/36 0.0 [ 0.0, 0.0 ]
Ma 2006 0/11 0/11 0.0 [ 0.0, 0.0 ]
Mayer 2006 0/32 1/8 0.09 [ 0.00, 2.05 ]
Shao 2006 0/151 0/81 0.0 [ 0.0, 0.0 ]
Johansson 2007 0/9 0/9 0.0 [ 0.0, 0.0 ]
Pugliese 2007 0/10 0/10 0.0 [ 0.0, 0.0 ]
Sachs 2007 1/36 0/13 1.14 [ 0.05, 26.25 ]
Bosch 2008 0/176 0/89 0.0 [ 0.0, 0.0 ]
Mayer 2008 14/558 4/263 1.65 [ 0.55, 4.96 ]
Narayan 2008 1/61 1/36 0.59 [ 0.04, 9.15 ]
Gill 2009 4/104 0/68 5.91 [ 0.32, 108.12 ]
Total (95% CI) 2134 1155 1.49 [ 0.72, 3.07 ]
Total events: 35 (rFVIIa), 8 (Control)
0.1 0.2 0.5 1 2 5 10
Favours rFVIIa Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 6.36, df = 9 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours rFVIIa Favours control
Analysis 3.4. Comparison 3 rFVIIa used prophylactically or therapeutically versus placebo (adverse events),
Outcome 4 Total arterial events.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 3 rFVIIa used prophylactically or therapeutically versus placebo (adverse events)
Outcome: 4 Total arterial events
Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Planinsic 2005 6/64 2/19 0.89 [ 0.20, 4.06 ]
Friederich 2003 1/24 0/12 1.56 [ 0.07, 35.67 ]
Bosch 2004 2/121 0/121 5.00 [ 0.24, 103.07 ]
Boffard 2005a 1/69 0/74 3.21 [ 0.13, 77.60 ]
Boffard 2005b 2/70 1/64 1.83 [ 0.17, 19.69 ]
Chuansumrit 2005 0/16 0/9 0.0 [ 0.0, 0.0 ]
Diprose 2005 2/10 2/10 1.00 [ 0.17, 5.77 ]
Lodge 2005a 2/132 0/68 2.59 [ 0.13, 53.28 ]
Mayer 2005a 16/303 0/96 10.53 [ 0.64, 173.88 ]
Mayer 2005b 4/36 0/11 2.92 [ 0.17, 50.37 ]
Pihusch 2005 5/77 0/23 3.38 [ 0.19, 59.02 ]
Raobaikady 2005 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ekert 2006 0/40 0/36 0.0 [ 0.0, 0.0 ]
0.01 0.1 1 10 100
Favours rFVIIa Favours control
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(. . . Continued)
Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ma 2006 0/11 0/11 0.0 [ 0.0, 0.0 ]
Mayer 2006 4/32 3/8 0.33 [ 0.09, 1.20 ]
Shao 2006 1/151 0/81 1.62 [ 0.07, 39.28 ]
Johansson 2007 0/9 0/9 0.0 [ 0.0, 0.0 ]
Pugliese 2007 0/10 0/10 0.0 [ 0.0, 0.0 ]
Sachs 2007 8/36 2/13 1.44 [ 0.35, 5.94 ]
Bosch 2008 3/176 0/89 3.56 [ 0.19, 68.16 ]
Mayer 2008 39/558 11/263 1.67 [ 0.87, 3.21 ]
Narayan 2008 6/61 4/36 0.89 [ 0.27, 2.93 ]
Gill 2009 4/104 1/68 2.62 [ 0.30, 22.90 ]
Hauser 2010a 16/224 11/250 1.62 [ 0.77, 3.42 ]
Hauser 2010b 2/46 1/40 1.74 [ 0.16, 18.47 ]
Total (95% CI) 2404 1445 1.45 [ 1.02, 2.05 ]
Total events: 124 (rFVIIa), 38 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.34, df = 18 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours rFVIIa Favours control
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Analysis 3.5. Comparison 3 rFVIIa used prophylactically or therapeutically versus placebo (adverse events),
Outcome 5 Total venous events.
Review: Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
Comparison: 3 rFVIIa used prophylactically or therapeutically versus placebo (adverse events)
Outcome: 5 Total venous events
Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Planinsic 2005 2/64 1/19 0.59 [ 0.06, 6.20 ]
Friederich 2003 0/24 0/12 0.0 [ 0.0, 0.0 ]
Bosch 2004 5/121 7/121 0.71 [ 0.23, 2.19 ]
Boffard 2005a 1/69 3/74 0.36 [ 0.04, 3.36 ]
Boffard 2005b 2/70 2/64 0.91 [ 0.13, 6.30 ]
Chuansumrit 2005 0/16 0/9 0.0 [ 0.0, 0.0 ]
Diprose 2005 0/10 0/10 0.0 [ 0.0, 0.0 ]
Lodge 2005a 4/132 3/68 0.69 [ 0.16, 2.98 ]
Mayer 2005a 4/303 2/96 0.63 [ 0.12, 3.41 ]
Mayer 2005b 1/36 1/11 0.31 [ 0.02, 4.49 ]
Pihusch 2005 3/77 0/23 2.15 [ 0.12, 40.24 ]
Raobaikady 2005 0/24 0/24 0.0 [ 0.0, 0.0 ]
Ekert 2006 0/40 0/36 0.0 [ 0.0, 0.0 ]
Ma 2006 0/11 0/11 0.0 [ 0.0, 0.0 ]
Mayer 2006 3/32 0/8 1.91 [ 0.11, 33.67 ]
Shao 2006 2/151 1/81 1.07 [ 0.10, 11.65 ]
Johansson 2007 0/9 0/9 0.0 [ 0.0, 0.0 ]
Pugliese 2007 0/10 0/10 0.0 [ 0.0, 0.0 ]
Sachs 2007 0/36 0/13 0.0 [ 0.0, 0.0 ]
Bosch 2008 6/176 7/89 0.43 [ 0.15, 1.25 ]
Mayer 2008 17/558 11/263 0.73 [ 0.35, 1.53 ]
Narayan 2008 7/61 1/36 4.13 [ 0.53, 32.23 ]
Gill 2009 3/104 0/68 4.60 [ 0.24, 87.67 ]
Hauser 2010a 29/224 24/250 1.35 [ 0.81, 2.25 ]
Hauser 2010b 0/46 4/40 0.10 [ 0.01, 1.75 ]
0.01 0.1 1 10 100
Favours rFVIIa Favours control
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(. . . Continued)
Study or subgroup rFVIIa Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 2404 1445 0.92 [ 0.67, 1.26 ]
Total events: 89 (rFVIIa), 67 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 12.59, df = 15 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours rFVIIa Favours control
A D D I T I O N A L T A B L E S
Table 1. Status of ongoing studies from 2007 Cochrane review
Author Population Expected
enrolment
Primary outcome Start date Status as of 23
March 2011
Arai 2005 Spontaneous ICH 90 TE serious adverse
events to 90 days
January 2006 Completed but not
yet published
Della Corte 2006 Post-surgical evalua-
tion of intracerebral
haematoma
Not stated Postopera-
tive rebleeding after
surgery
Jan 2005 See Imberti 2005
Gaspar-Blaudschun
2004
Post-cardiac surgery Not stated Se-
rious adverse events
within 30 days
October 2004 to
November 2007
Completed. See Gill
2009.
Gris 2006 Post-partum
haemorrhage refrac-
tory to other treat-
ment
Not stated Intensity of haemor-
rhage before and af-
ter VIIa; units trans-
fused
December 2006 Recruiting
Imberti 2005 Post-surgical evalua-
tion of intracerebral
haematoma
Not stated Postopera-
tive rebleeding after
surgery
Jan 2005 to Decem-
ber 2008
Completed but not
yet published
Iorio 2006 ICH in setting of
oral anticoagulants
or antiplatelets
Not stated Change in ICH vol-
ume at 24 hours
September 2005 Recruiting
Kelleher 2006 Post-cardiac surgery Not stated Critical serious ad-
verse events
2006 Completed but not
yet published
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Table 1. Status of ongoing studies from 2007 Cochrane review (Continued)
McCall 2005 Com-
plex cardiac surgery
as salvage treatment
40 Adequate
haemostasis to en-
able chest closure
June 2005 Recruiting
Molter 2005 Burn excision and
grafting
52 Perioperative blood
loss and transfusion
January 2006 Recruiting
Ng 2006 ECMO patients
post-cardiac surgery
Not stated Postoperative bleed-
ing and transfusion
April 2004 Status unknown
Tortella 2006 Trauma 1502 Mortality and mor-
bidity through day
30
May 2006 Ter-
minated early. See
Hauser 2010a and
Hauser 2010b
EMCO = extracorporeal membrane oxygenation; ICH = intracranial haemorrhage; TE = thromboembolic
Table 2. Prophylactic RCT - overview
Study Participants N Intervention Co-Intervention(s) Primary outcome
Diprose 2005 Complex non-coro-
nary cardiac surgery
requiring CPB
20 1 dose of 90 µg/kg rFVIIa
iv
Transfusion for Hb < 8.5
g/dL
Intraoperative cell salvage
Aprotinin
Protamine for heparin re-
versal
Number of patients re-
ceiving allogeneic transfu-
sion
Ekert 2006 Infants < 1 year with
congenital heart dis-
ease requiring CPB
82 First dose of 40 µg/kg
rFVIIa iv; repeated up to
2 times if ongoing bleed-
ing
No transfusion protocol
stated
Protamine for heparin re-
versal
Time to chest closure af-
ter reversal of heparin and
transfusion requirements
Essam 2007 Elective cardiac
revascularisation re-
quiring CPB
30 1 dose of 90 µg/kg rFVIIa
iv
Transfusion for Hb < 7 g/
dL
Intraoperative cell salvage
Protamine for heparin re-
versal
No stated primary out-
come but blood loss and
transfusion requirements
measured
Friederich 2003 Retropubic prostate-
ctomy
36 1 dose of 20 µg/kg or 40
µg/kg rFVIIa iv
Transfusion for Hb < 8 g/
dL intraoperatively and <
10 g/dL postoperatively
LMWH postoperatively
Blood loss and transfusion
requirements
Gill 2009 Adult patients un-
dergoing car-
diac surgery requir-
179 1 dose of 40 µg/kg or 80
µg/kg of rFVIIa
Clearly defined transfu-
sion protocol to maintain
Hb > 8.0 g/dL
Death, cerebral
infarction, myocardial in-
farction, pulmonary em-
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Table 2. Prophylactic RCT - overview (Continued)
ing CPB bolism and other throm-
boembolic events
Hanna 2010 Paediatric pa-
tients of ASA class I
and II with congen-
ital craniofacial mal-
formation under-
going reconstructive
surgery
45 First dose of 100 µg/kg
at hour 0 over 15 minutes
followed by infusion of 10
µg/kg/h until skin closure
Transfusion for Hb < 9 g/
dL.However, blood trans-
fusion was instituted im-
mediately whenever se-
vere blood loss occurred
or was anticipated
Primary endpoints were
not clearly stated, but pe-
rioperative blood loss and
transfusion requirements
measured
Jeffers 2002 Cirrhosis and coagu-
lopathy undergoing
laparoscopic liver
biopsy
66 1 dose of 5 µg/kg, 20 µg/
kg, 80 µg/kg or 120 µg/
kg rFVIIa iv
No transfusion protocol
stated
Time to haemostasis and
duration of normal PT
Johansson 2007 Thermal burn un-
dergoing skin exci-
sion and grafting
18 First dose of 40 µg/kg
rFVIIa iv; 2nd dose given
at 90 minutes later
Transfusion for Hb < 10
g/dL; platelet count < 80 x
109/L; and FFP in 1:1 ra-
tio to RBCs for microvas-
cular bleeding
LMWH postoperatively
Transfusion requirements
Lodge 2005a Partial hepatectomy 204 First dose of 20 µg/kg or
80 µg/kg rFVIIa iv; 2nd
dose given at 5 hours if
operation longer than 6
hours
Transfusion for Hct <
25% and platelet count <
30 x 109/L
LMWH postoperatively
Number of patients re-
ceiving allogeneic transfu-
sion
Lodge 2005b Liver
transplantation
209 First dose of 60 µg/kg or
120 µg/kg rFVIIa iv; re-
peated every 2 hours until
end of surgery
Transfusion for Hct <
25%, platelet count < 30
x 109/L; and coagulation
ratios > 1.5 times normal
Transfusion requirements
Ma 2006 Cardiac valve re-
placement requiring
CPB
22 1 dose of 40 µg/kg rFVIIa
iv
No transfusion protocol
stated
Protamine for heparin re-
versal
No stated primary out-
come but blood loss and
transfusion requirements
measured
Planinsic 2005 Liver
transplantation
87 1 dose of 20 µg/kg, 40µg/
kg or 80 µg/kg rFVIIa iv
Transfusion for Hct <
25%, platelet count < 30
x 109/L; and coagulation
ratios > 1.5 times normal
Transfusion requirements
Pugliese 2007 Liver
transplantation
20 1 dose of 40µg/kg rFVIIa
iv
Transfusion forHb < 10g/
dL and INR > 1.5
No stated primary out-
come but blood loss and
transfusion requirements
measured
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Table 2. Prophylactic RCT - overview (Continued)
Raobaikady 2005 Re-
constructive surgery
for traumatic pelvic
fractures
48 First dose of 90 µg/kg
rFVIIa iv; 2nd dose given
at 2 hours if ongoing
bleeding
Transfusion for Hb < 8 g/
dL; platelet count < 100
x 109/L; and coagulation
ratios > 1.5 times normal
Intraoperative cell salvage
LMWH perioperatively
Blood loss
Sachs 2007 Spinal fusion
surgery
60 First dose of 30 µg/kg,
60 µg/kg or 120 µg/kg
rFVIIa iv at dosing trig-
ger; repeated in 2 and 4
hours after initial dose
Transfusion for Hb < 9
g/dL; platelet count < 75
x 109/L; and coagulation
ratios > 1.5 times normal
Topical haemostatic
agents
Adverse events and blood
loss
Shao 2006 Partial hepatectomy 235 First dose of 50 µg/kg or
100 µg/kg rFVIIa iv; re-
peated every 2 hours un-
til end of surgery to max-
imum of 4 doses
Transfusion if RBC loss >
500 mL
Aprotinin if critical bleed-
ing
Number of patients re-
ceiving allogeneic transfu-
sion and transfusion re-
quirements
CPB = cardiopulmonary bypass; Hb = haemoglobin; Hct = haematocrit; INR = international normalised ratio; iv = intravenous;
LMWH = low molecular weight heparin; N = number of patients randomised; RBC = red blood cell; rFVIIa = recombinant factor
VIIa
Table 3. Therapeutic RCT - overview
Study Participants N Intervention Co-intervention(s) Primary outcome
Boffard 2005a Blunt trauma 158 First dose of 200 µg/kg
rFVIIa iv; repeated doses
of 100 µg/kg at 1 and 3
hours after initial dose
No transfusion protocol
stated
Transfusion requirements
Boffard 2005b Penetrating trauma 143 First dose of 200 µg/kg
rFVIIa iv; repeated doses
of 100 µg/kg at 1 and 3
hours after initial dose
No transfusion protocol
stated
Transfusion requirements
Bosch 2004 Upper gastrointesti-
nal haemorrhage in
patients with cirrho-
sis
245 First dose of 100 µg/kg
rFVIIa iv; repeated doses
at 2, 4, 6, 12, 18, 24 and
30 hours after initial dose
Transfusion to maintain
Hct 25% to 30%
Vasoactive therapy
Endoscopic therapy
Combined endpoint of
control of bleeding or re-
bleeding or death
Bosch 2008 Upper gastrointesti-
nal haemorrhage in
patients with cirrho-
sis
265 First dose 200 µg/kg
rFVIIa iv; repeated doses
at 2, 8, 14 and 20 hours
after initial dose; or repeat
Transfusion to maintain
Hct 25% to 30% and for
platelet count < 30 x 109/
L
Combined endpoint of
control of bleeding or re-
bleeding or death
115Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Therapeutic RCT - overview (Continued)
dose 2 hours after initial
dose
Vasoactive therapy
Endoscopic therapy
Prophylactic antibiotic
therapy
Chuansumrit 2005 Children
with dengue haem-
orrhagic fever
28 First dose of 100 µg/kg
rFVIIa iv; repeated dose
at 30 minutes if ongoing
bleeding
No transfusion protocol
stated
Nasal packing for epis-
taxis
Ranitidine or omeprazole
Change in bleeding
Hauser 2010a Adult patients who
had sustained blunt
trauma
481 First dose of 200 µg/kg
of rFVIIa at 0 hour; re-
peated doses of 100 µg/
kg at 1 hour and 3 hours
Evidence-
based guidelines and pro-
tocols to maintain Hb 8
to 10 g/dL for first 24
hours and Hb > 7 g/dL
thereafter (unless haemo-
dynamically unsta-
ble) Platelets to maintain
> 50 x 109/L and FFP/
cryoprecipitate to main-
tain INR<1.5 or if bleed-
ing
1st tier endpoint was su-
periority in all-cause 30-
day mortality in blunt
trauma. If not met, the 2
nd
tier primary conditional
endpoint of non-inferior-
ity of mortality and su-
periority on durable mor-
bidity was applied
Hauser 2010b Adult patients who
had sustained pene-
trating trauma
92 First dose of 200 µg/kg
of rFVIIa at 0 hour; re-
peated doses of 100 µg/
kg at 1 hour and 3 hours
Evidence-
based guidelines and pro-
tocols to maintain Hb 8
to 10 g/dL for first 24
hours and Hb > 7 g/dL
thereafter (unless haemo-
dynamically unsta-
ble) Platelets to maintain
> 50 x 109/L and FFP/
cryoprecipitate to main-
tain INR<1.5 or if bleed-
ing
1st tier endpoint was su-
periority in all-cause 30-
day mortality in blunt
trauma. If not met, the 2
nd
tier primary conditional
endpoint of non-inferior-
ity of mortality and su-
periority on durable mor-
bidity was applied
Mayer 2005a Spontaneous ICH 400 1 dose of 40 µg/kg, 80
µg/kg or 160 µg/kg of
rFVIIa iv
No transfusion protocol
stated
Medicalmanagement fol-
lowing AHA guidelines
Change in volume of
ICH
Mayer 2005b Spontaneous ICH 48 1 dose of 10 µg/kg, 20
µg/kg, 40 µg/kg, 80 µg/
kg, 120µg/kg or 160µg/
kg of rFVIIa iv
No transfusion protocol
stated
Medicalmanagement fol-
lowing AHA guidelines
Adverse events
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Table 3. Therapeutic RCT - overview (Continued)
Mayer 2006 Spontaneous ICH 41 1 dose of 5µg/kg, 20µg/
kg, 40µg/kg or 80µg/kg
of rFVIIa iv
No transfusion protocol
stated
Medicalmanagement fol-
lowing AHA guidelines
Adverse events
Mayer 2008 Spontaneous ICH 841 1 dose of 20 µg/kg or 80
µg/kg of rFVIIa iv
No transfusion protocol
stated
Medicalmanagement fol-
lowing AHA guidelines
Severe disability or death
Narayan 2008 Traumatic ICH 97 1 dose of 40 µg/kg, 80
µg/kg, 120 µg/kg, 160
µg/kg or 200 µg/kg of
rFVIIa iv
No transfusion protocol
stated
Adverse events
Pihusch 2005 Post-haematopoi-
etic stem cell trans-
plantation
100 First dose of 40µg/kg, 80
µg/kg or 160 µg/kg; re-
peated every 6 hours x 6
doses
Transfusion for Hb < 8 g/
dL and platelet count <
20 x 109/L (< 75 x 109/
L in haemorrhagic cystitis
or diffuse alveolar haem-
orrhage)
Heparin, defibrotide,
NSAIDs
Change in bleeding
AHA = American Heart Association; FFP = fresh frozen plasma; Hb = haemoglobin; Hct = haematocrit; ICH = intracranial haemor-
rhage; INR = international normalised ratio; iv = intravenous; N = number of patients randomised; NSAID = non-steroidal anti-
inflammatory drug; rFVIIa = recombinant factor VIIa
A P P E N D I C E S
Appendix 1. CENTRAL search strategy (The Cochrane Library)
#1 FACTOR VIIA single term (MeSH)
#2 factor viia OR factor 7a OR rfviia OR fviia
#3 (activated NEAR/2 factor seven) OR (activated NEAR/2 factor vii) OR (activated NEAR/2 rfvii) OR (activated NEAR/2 fvii)
#4 novoseven* OR novo seven* OR eptacog* OR proconvertin* or novo7
#5 (factor seven OR factor vii OR factor 7):ti
#6 #1 OR #2 OR #3 OR #4 OR #5
#7 HEMORRHAGE explode all trees (MeSH)
#8 hemorrhag* or haemorrhag* OR bleed* OR bloodloss* OR blood NEAR/3 los* OR ICH
#9 HEMOSTASIS explode all trees (MeSH)
#10 hemosta* OR haemosta* OR surg* or operat* OR perioperat* OR resect* OR transplant* OR *tomy OR trauma* or transfus* or
emergenc* or polytrauma* or injur* or accident*
#11 #7 OR #8 OR #9 OR #10
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#12 #6 AND #11
Appendix 2. MEDLINE (Ovid) search strategy
1. FACTOR VIIA/
2. (factor viia OR factor 7a OR rfviia OR fviia).tw.
3. ((activated adj2 factor seven) OR (activated adj2 factor vii) OR (activated adj3 rfvii) OR (activated adj2 fvii)).tw.
4. (novoseven* OR novo seven* OR eptacog* OR proconvertin OR novo7).tw.
5 (factor seven OR factor vii OR factor 7).ti.
6. or/1-5
7. exp HEMORRHAGE/
8. (hemorrhag* OR haemorrhag* OR bleed* or bloodloss* or blood loss* OR ICH).tw.
9. exp HEMOSTASIS/
10. (hemosta* OR haemosta* or surg* or operat* or resect* or perioperat* or trauma* or transfus* or emergenc* or polytrauma* or
injur* or accident*).tw.
11. or/7-10
12. 6 AND 11
Appendix 3. EMBASE (Ovid) search strategy
1. BLOOD CLOTTING FACTOR 7A/
2. (factor viia OR factor 7a OR rfviia OR fviia).mp.
3. ((activated adj3 factor seven) OR (activated adj3 factor vii) OR (activated adj3 rfvii) OR (activated adj3 fvii)).mp.
4. (novoseven* OR novo ADJ seven* OR eptacog* OR proconvertin).mp.
5. or/1-4
6. exp BLEEDING/
7. (hemorrhag* OR haemorrhag* OR bleed* or bloodloss* or blood near los* OR ICH).mp.
8. HEMOSTASIS/
9. (hemosta* or haemosta*).mp.
10. (surg* or operat* or resect* or perioperat* or trauma* or transfus* or emergenc* or polytrauma* or injur* or accident*).mp.
11. or/6-10
12. 5 AND 11
Appendix 4. CINAHL (NHS Evidence) search strategy
1. (factor AND viia OR factor AND 7a OR rfviia OR fviia).ti,ab
2. ((activated adj2 factor seven) OR (activated adj2 factor vii) OR (activated adj3 rfvii) OR (activated adj2 fvii)).ti,ab
3. (novoseven* OR novo AND seven* OR eptacog* OR proconvertin or novo7).ti,ab
4. (factor seven OR factor vii OR factor 7).ti
5. 1 OR 2 OR 3 OR 4
6. exp HEMORRHAGE/
7. (hemorrhag* OR haemorrhag* OR bleed* OR bloodloss* OR blood AND loss* OR ICH).ti,ab
8. exp HEMOSTASIS/
9. (hemosta* OR haemosta* OR surg* OR operat* OR resect* OR perioperat* OR trauma* OR transfus* OR emergenc* OR
polytrauma* OR injur* OR accident*).ti,ab
10. 6 OR 7 OR 8 OR 9
11. 5 AND 10
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Appendix 5. OTHER STRATEGIES
PUBMED
(“activated factor vii” OR “activated factor seven” OR “recombinant factor vii” OR “factor viia” OR rfviia OR fviia OR “activated
rfvii” OR “activated fvii”) AND (randomi* OR randomly OR trial OR groups)
LILACS/KoreaMed/IndMed/PakMediNet
factor viia OR activated factor vii OR activated fvii OR activated rfvii OR rfviia OR fviia OR novoseven OR novo seven
TRANSFUSION EVIDENCE LIBRARY/ISRCTN REGISTER/WHO ICTRP Database/EUDRACT (EU Clinical Trials Regis-
ter)/ClinicalTrials.gov
“factor viia” OR “factor seven” OR rfviia OR fviia OR novoseven OR “activated factor seven” OR “activated factor vii” OR “activated
rfvii” OR “activated fvii”
WH A T ’ S N E W
Last assessed as up-to-date: 23 March 2011.
Date Event Description
23 March 2011 New search has been performed The search for studies was updated to 23 March 2011.
H I S T O R Y
Protocol first published: Issue 4, 2004
Review first published: Issue 2, 2007
Date Event Description
12 September 2011 New citation required but conclusions have not
changed
The search was updated to 23 March 2011. Four new
trials have been included in the review.TheResults and
Discussion sections have been amended accordingly.
The authors of the review have changed
29 July 2009 New search has been performed The search was updated to 25 February 2009. Twelve
new trials have been included in the review. The Re-
sults and Discussion sections have been amended ac-
cordingly. The authors of the review have changed
1 May 2008 Amended Converted to new review format.
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